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Cataract is one of the leading causes of vision loss worldwide. The rate of cataract 
surgery has been steadily increasing. Toxic Anterior Segment Syndrome (TASS) is a 
sterile inflammatory response in the anterior segment of the eye that may occur following 
cataract surgery. When left untreated, it can lead to permanent vision loss. Corneal 
endothelial cells are the cells most affected by TASS. These cells are unable to reproduce 
in vivo and consequently once the density of these cells drops below a certain level, 
vision is reduced and cannot be reversed. The damage is thought to be mediated by 
cytokines and endotoxins, primarily through the NF-κΒ pathway. It is hypothesized that 
anti-inflammatory drug delivery intraocular lenses may help reduce the occurrence of 
TASS and consequent vision loss. In this research thesis project, an in vitro model was 
developed as a tool to select drug and delivery material to be used in an anti-TASS 
ophthalmic biomaterial. In an attempt to find a novel and more effective approach to 
TASS prevention, dexamethasone, a potent anti-inflammatory steroid drug, was 
compared to triptolide, a cytokine inhibitor; aprotinin, a general protease inhibitor; and 
PPM-18, a NF-κΒ inhibitor. To assess the efficacy of these drugs, an in vitro assay using 
human umbilical vein endothelial cells (HUVEC) and lipopolysaccharide as a stimulant 
was developed. Cell response to dexamethasone (10 nM), triptolide (3 nM), aprotinin 
(20 µM) and PPM-18 (10 µM) with or without LPS was characterized by cell viability 
and flow cytometry analysis of cell activation. Activation was characterized using 
markers for cell adhesion and activation ICAM-1, PECAM-1, VCAM-1, β1-integrin, 
CD44 and E-selectin. Following preliminarily testing, the efficacy of dexamethasone 
(10 nM) and PPM-18 (10 µM) loaded polymer (PDMS) and copolymer 
(PDMS/pNIPAAm) interpenetrating polymer networks were evaluated over a 4 day 
release period. The results from soluble drug and LPS (100 ng/mL) testing indicated no 
decrease in cell viability after 24 h. Dexamethasone, triptolide, aprotinin, and PPM-18 
did not reduce the significant ICAM-1 upregulation seen in HUVECs after exposure to 
LPS for 4 days. PPM-18 in combination with LPS significantly upregulated E-selectin 
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and CD44 from unstimulated HUVEC cells. The polymer materials without drug loading 
did not influence the cell phenotype. However, PPM-18 delivering polymer and 
copolymer materials significantly upregulated VCAM-1, CD44 when compared to all 
other treatments. Propidium iodide uptake in HUVEC exposed to PPM-18 drug 
delivering polymer and copolymer treatments indicated that these treatments caused cell 
necrosis. None of the drugs, or the drug delivering materials were shown to counteract 
the upregulation seen from LPS stimulation of HUVEC cells. Future work should focus 
on validating the in vitro model to more closely replicate the in vivo environment of the 
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Cataracts cause around half of all visual disabilities and blindness worldwide [1]. 
Consequently, cataract surgery is one of the most commonly performed surgeries in the 
world and is relatively safe [1,2]. Cataract surgery is most commonly performed using a 
technique known as phacoemulsification. This requires a small incision along the edge of the 
cornea through which a needle vibrating at ultrasonic levels emulsifies and aspirates the 
crystalline lens [3–5]. An intraocular lens (IOL) is then inserted through the incision to 
replace the removed lens [3,4]. The physical trauma from cataract surgery can influence the 
inflammatory response in the eye even without the presence an infectious agent or irritant 
[4,6]. For this reason, along with possible infections from surgery, anti-inflammatory agents 
including steroids, antibiotics, and non-steroidal anti-inflammatory drugs (NSAIDs) are used 
prophylactically to prevent complications [6].  
As with any surgery, complications may arise that if left untreated could worsen the initial 
conditions of the patient. Two of the most devastating cataract complications are toxic 
anterior segment syndrome (TASS) and endophthalmitis [3,7–12]. TASS is an acute sterile 
inflammatory response that typically occurs within 48 h post surgery [3,7–9,13]; whereas, 
endophthalmitis is an infection of the anterior segment of the eye due to bacterial, parasitic or 
fungal infection [10–12]. Endophthalmitis is most commonly due to Gram-positive bacteria 
[11,12,14]. Depending on the study, the incidence rate for TASS varies between 0.04 to 
0.68% [2,5,15–20]. To prevent its occurrence, many perioperative, intraoperative, and 
postoperative measures are taken [16,21]. Both of these diseases, if left untreated may lead to 
permanent vision loss and possible blindness through damage to the corneal endothelium 
[5,7–9,11–13,22–24].  
The human cornea is composed of three major layers, the epithelium, the stroma, and the 
endothelium [3,25–28]. During cataract surgery the corneal endothelium has the potential to 
become damaged, and unlike the stroma and epithelium, the human corneal endothelium is 
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unable to replicate [28–33]. The primary function of the corneal endothelium is to maintain 
hydration and clarity in the eye [3,25,28,34,35]. Healthy corneal endothelial cells are 
hexagonal in appearance and a proper arrangement of these cells allows them to maintain 
their functionality [3,25,28,34,36–42]. As cell numbers decrease through aging or damage, 
the cells enlarge to compensate and are less efficient in maintaining the necessary pressure 
for clarity [3,25,28,34,36–44]. If the number of corneal endothelial cells drops below a 
certain level, vision loss and blindness occurs [42,43]. Various drugs are thus used to reduce 
the risk of potential damage to the endothelium during cataract removal and IOL 
implantation.    
In the case of the eye, drug can be administered in various ways. Topical application of 
drugs, via eye drops or ointments, allows only 5% to 10% of the applied amount to reach the 
endothelium and anterior segment [14,45–47]. Intraocular injections are common, but 
invasive and uncomfortable to the patient, while also introducing the further possibility of 
infection into the anterior segment [14,45,48,49]. Drug delivering devices are increasingly 
used to deliver drugs immediately to the site of implantation, which allows for smaller 
amounts of drug needed to provide a therapeutic effect locally [48].   
This thesis reports the results of in vitro assays that were performed to support our 
hypothesis that anti-inflammatory drug delivery intraocular lenses (IOLs) may help reduce 
the occurrence of TASS and consequent vision loss. In this research thesis project, an in vitro 
model was developed as a tool to select drug and delivery material to be used in an anti-
TASS ophthalmic biomaterial in an attempt to find a novel and more effective approach to 
TASS prevention. In chapter 1, a review of the current literature is presented on corneal 
endothelial cells. Chapter 2 focuses on TASS and endophthalmitis mechanisms, current 
treatment methods, along with in vitro models and the thesis research question. The methods 
used to test our thesis research question are presented in Chapter 3. Chapter 4 presents our 
findings related to viability and cellular phenotype expression on cells. Discussion of our 
findings is given in Chapter 5. Conclusions are presented in Chapter 6 along with presenting 
recommendations for future work. 
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1.2 Corneal Endothelial Cells 
The cornea is composed of different layers each with its distinct type of cells. The three 
primary cell types are epithelial, stromal keratocytes, and endothelial, as shown in Figure 1  
[3,25–28,50]. Each layer possesses different properties and roles within the cornea.  
 
Figure 1: Light micrograph of human cornea and diagram indicating the various layers 
of the cornea. The stroma is not labelled, but is the area between Bowman’s membrane and 
Descement’s membrane. 
Reprinted from Journal of Cataract & Refractive Surgury, 37(3), DelMonte DW,  Kim T, 
Anatomy and physiology of the cornea, 588-598., Copyright (2011), with permission from 
Elsevier. 
 
Corneal endothelial cells (CEC) form a monolayer on the posterior side of the cornea. This 
layer is clear, transparent, and avascular, and contains many sensory nerves supplied from the 
corneal stroma [3,25,28,35,38]. Healthy endothelial cells have a hexagonal appearance, 
shown in Figure 2. As function and health deteriorate, either with age or injury, CEC become 
increasingly polygonal (pleomorphism) and increase in size (polymegathism) (see Figure 3) 





 at birth to around 2600 cells/mm
2
 in adult eyes [3,28,43,44], leading to 
further risk of CEC damage causing vision loss. Corneal function and transparency is 




Figure 2: Right (OD) and left (OS) eye images of a healthy corneal endothelium. Their 
cellular densities are 3081 and 3253 respectively. Both show minimal pleomorphism or 
polymegathism prior to cataract surgery. 
Reprinted from Journal of Cataract & Refractive Surgery, 32, Moshirfar M, Whitehead G, 
Beutler BC, Mamalis N, Toxic anterior segment syndrome after Verisyse iris-supported 








Figure 3: Right (OD) and left (OS) eye one year following cataract surgery that led to 
TASS infection in the right eye. Final cell densities were 964 and 3136. The right eye also 
demonstrates an increase in pleomorphism and polymegathism. 
Reprinted from Journal of Cataract & Refractive Surgery, 32, Moshirfar M, Whitehead G, 
Beutler BC, Mamalis N, Toxic anterior segment syndrome after Verisyse iris-supported 
phakic intraocular lens implantation, 1233-1237, Copyright (2006), with permission of 
Elsevier.  
 
Cataract surgery causes damage and decreased cell density in the CEC, especially near the 
incision site [42]. Also, a cornea that is damaged during surgery experiences an accelerated 
rate of endothelial deterioration [42]. In combination with CEC lost through aging, this may 
accelerate vision loss in the elderly, so steps should be taken to minimize CEC damage 
during and following surgery; drug administration can be one of the preventative measures. 
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Following an injury, an inflammatory stimulus, or as part of the normal aging process, 
cells may die. Cell death mechanism can be categorized as either apoptosis or necrosis. 
Apoptotic cell death is a programmed cell death in response to cytokines and stress stimuli 
[51–53]. Cells undergoing apoptosis shrink, followed by blebbing of the cell membrane, and 
finally fragmentation of the cell into membrane bound bodies [52,53]. Apoptosis helps to 
reduce the damage to the surrounding cells [51]. Necrosis typically occurs in response to 
toxins, physical injury, or restricted blood flow [53]. Necrotic cells swell and their 
extracellular membrane is disrupted, which allows cellular contents to be lost from the cell. 
This leads to a severe inflammatory response [53]. In endothelial cells, lipopolysaccharide 
(LPS) and tissue necrosis factor alpha (TNF-α) induce an inflammatory response and 
apoptosis, but not necrosis [54]. 
In CEC, the reasons for apoptotic cell death are not well understood. Metabolic changes, 
mechanical stress, endotoxins, inflammatory cytokines, and nutrient deprivation are thought 
to be possible causes for triggering apoptosis [44,55,56]. The responses to cytokines often 
occur through the nuclear factor – kappa beta (NF-κβ) and nitric oxide pathways [56].  
NF-κΒ is a transcription factor that can induce an inflammatory (activation) response, 
and/or an apoptotic response, and through its activation can also control cell proliferation, 
adhesion, invasion and angiogenesis in many cell types [57–59]. It is activated by many 
different mechanisms and pathways including cytokines, such as TNF-α, and endotoxins, 
such as LPS [57,58]. NF-κΒ is bound to an inhibitor (IκΒ) in the cytoplasm of cells, and 
activation involves processes that lead to translocation of NF-κΒ to the nucleus of the cell 
[57,59–61]. As shown in Figure 4, regardless of the activation pathway there are four 
primary steps leading to NF-κΒ activation [58,59]. When activated, NF-κΒ induces the 




Figure 4: NF-kb activation pathway showing three possible activation pathways. TNFa 
is the example of an inflammatory cytokine, and the pathway of relevance in this 
research study. 
Reprinted from Trends in Pharmacological Sciences, 30(6), Sethi G, Tergaonkar V, Potential 
pharmacological control of the NF-κΒ pathway, 313-321, Copyright (2009), with permission 
of Elsevier.  
 
The inflammatory response elicits a change in the phenotype of the endothelial cell and the 
various receptors they express. These membrane receptors (also referred to as activation 
markers) are either up or down regulated in response to an inflammatory stimulus. In 
endothelial cells, including CEC, the most common markers are intercellular adhesion 
molecule-1 (ICAM-1, CD54), platelet endothelial cell adhesion molecule (PECAM-1, 
CD31), vascular cell adhesion molecule (VCAM-1, CD106), β1-integrin (CD29), CD44 and 
 
 8 
CD62 antigen like family member E (E-selectin, CD62E). Their response to cytokines or 
inflammatory stimulus is summarized in Table 1. The corneal endothelium is also highly 
sensitive to toxic agents, so any medicine or device used during surgery needs to be properly 
chosen for correct pH, osmolarity, and chemical composition to prevent cell activation and 
severe damage or apoptosis [13,15,56,63].  
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 endothelial cell adhesion molecule [64–69] 
 promotes endothelial cell-leukocyte interactions [64,65,68] 




 cell adhesion molecule present in all human cells [72] 
 promotes endothelial-leukocyte interactions [72] 
 upregulated during inflammatory stimulus such LPS [73,74] 
PECAM-1 
(CD31) 
 endothelial cell adhesion and signaling receptor [75,76] 
 increases to maintain membrane permeability in response to 
stimulation by TNF-α, TCM, IL-1, and LPS [75,77]
 
 
CD44  transmembrane endothelium glycoprotein adhesion molecule 
[78,79] 
 involved in lymphocyte adhesion to endothelium [79,80] 
 upregulated by LPS stimulation [78] 
E-selectin 
(CD62E)  
 endothelial cell adhesion molecule [67,69] 
 promotes endothelial-neutrophil adherence [64,68] 
 increases in short term response (<24 h) to TNF-α and LPS 
[64,67–70] 





 endothelial cell adhesion molecule [64,68] 
 recruits monocytes, leukocytes, lymphocytes, and T-cells 
[64,68,82] 






1.2.1 Cornea pump-leak mechanism for controlling corneal hydration 
The main purpose of the corneal endothelium is to maintain dehydrated levels in the stroma 
(deturgescence) and clarity of the cornea [3,28,56]. This is achieved through a barrier 
function and a pump-leak mechanism that was first described by Maurice in 1957, and 
remains the accepted theory today [83,84].  For the barrier function to work, there must be a 
sufficient number of CEC to cover the posterior surface of the cornea and maintain integrity 
of the intercellular tight junctions between CEC [3,44]. This barrier function is somewhat 
permeable because it permits an ion flux to establish the osmotic gradient [28,85]. The 
barrier formed prevents the bulk flow of liquid from the anterior segment to the stroma, but 
still allows diffusion of nutrients and other metabolites through the intracellular spaces 
[3,28,42,44]. A change in the barrier function of the CEC is characteristic in many corneal 
diseases or during surgical procedures, such as TASS and cataract surgery respectively [44]. 
The pump-leak mechanism pumps sodium (Na
+
) and bicarbonate (HCO
3+
) ions across the 
endothelial barrier from the stroma to the anterior segment [3,28,43]. One of the key proteins 





ATPase) [28,43,44]. This allows for fluid to passively leave the stroma into the anterior 
segment, which allows for the stroma to remain in its desturged state [28], even if there is a 




-ATPase pump increases activity to 
compensate for increased permeability through the CEC layer as necessary due to disease or 
age related degeneration [3].  
The barrier integrity between CEC must be maintained in order to properly control the 
CEC’s pump-leak mechanism [42,43,86]. This resistance to fluid leak is controlled by the 
tight junctions  of the endothelium [43,86], a supramolecular assembly found close to the 
apical domains of the endothelial cells in a monolayer [43]. In the CEC, the tight junction 
only offers weak resistance to the passage of solutes and water, which is believed to be due to 
an incomplete belt of the molecules present [86,87].   
The tight junctions allow cell signalling to control the pump-leak mechanism [86]. They 
are made up of  transmembrane molecules,  typically zonula-occludins-1 (ZO-1), claudins, 
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and the junctional adhesion molecule-A (JAM-A) [33,43,86,88]. The rate of corneal swelling 
can be linked to their degree of disintegration and consequent increase in permeability of 
solutes [42]. This leakiness of tight junctions allows the stroma to maintain its state of 
deturgescence [42,43,86]. Cataract surgery has been shown to significantly impair the barrier 
function of CEC, leading to increased IOP and reduced vision [42].  
 Many molecules associated with inflammatory stress, such as TNF-α, break down 
components of the tight junctions and create intercellular gaps that reduce the barrier 
integrity of the CEC [43]. The integrity of the barrier is often lost due to selective targeting of 




-ATPase of tight junctions 
[44,86–88]. The sensitivity of tight junctions to various substances shows the importance of 
carefully selecting wash solutions and drugs used during and after cataract surgery in the 




IOL Complications and Treatments 
2.1 Toxic Anterior Segment Syndrome (TASS)  
Toxic anterior segment syndrome (TASS) is a sterile postoperative inflammatory reaction 
caused by a non-infectious agent in the anterior segment leading to toxic damage of the 
corneal endothelium [3,9,13,90]. In the past, TASS was often referred to as sterile 
endophthalmitis, since it is not caused by bacterial, viral, or fungal infection of the eye [13]. 
Endophthalmitis and TASS also differ due to the location in the eye, as shown in Figure 5, 
with TASS occurring only in the anterior segment and endophthalmitis occurring anywhere 
in the ocular cavity [13].  
 
Figure 5: Diagram indicating the location of TASS and endophthalmitis. TASS presents 
only in the anterior segment of the eye; whereas, infectious endophthalmitis may present 
itself both in the anterior segment as well as the vitreous of the eye. 
Reprinted from Journal of Cataract & Refractive Surgery, 32, Mamalis N, Edelhauser HF, 
Dawson DG, Chew J, LeBoyer RM, Werner L, Toxic Anterior Segment Syndrome, 324-333, 





Common symptoms of TASS are blurry vision, mild or moderate ocular pain, and eye 
redness after surgery, with inflammation of the anterior segment within 12-48 hours post 
surgery [3,9,13,15,90]. TASS usually appears after uneventful cataract surgery; however, 
there have been a few cases of TASS appearing after penetrating keratoplasty [22]. 
Permanent edema and vision loss may result from TASS, which is initially related to acute 
breakdown of the endothelial tight junctions, and consequently the loss of barrier function 
and vision [3,9,13,15,90,91]. However, with treatment, some, if not complete, vision in 
patients can be restored and other symptoms significantly improved or eliminated [22,92,93].   
 
2.1.1 TASS diagnosis 
Corneal edema from widespread endothelial cell damage is commonly found in TASS 
patients, resulting in blurred vision, and occasionally, aqueous flare, and an anterior segment 
reaction with cell flare, and fibrin formation [3,9,15,90,91]. Diagnosis of TASS is based on 
the timing and severity of the symptoms following surgery. TASS typically occurs within 12-
48 h post surgery [3,9,13,15,90]. Eyes expressing a mild to moderate grade of TASS 
characteristically have low levels of corneal endothelial cell density, high coefficient of 
variation in the cell area, and a low mean percentage of hexagonal cells [3].  
 
2.1.2 TASS causes 
There have been many causes for the development of TASS after cataract surgery, all which 
show the sensitivity of the CEC to foreign agents in the anterior segment. A complete 
summary of possible TASS causes is given in Table 2. The CEC show severe sensitivity to 
preservatives as well as heat stable LPS [3,9,13]. TASS is due to inadequate sterilization, or 
contamination of the sterilization of the surgical equipment used [3,13,91]. Unfortunately, 
heat-stable LPS remain enzymatically active following autoclaving. If these are present in 
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irrigating solutions or medications, they can be injected into the anterior segment and lead to 
severe inflammation [3,9,13].  
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Table 2: Possible causes of TASS [3,9,15,90] 




 Incomplete chemical composition 
 Incorrect pH 
o <6.5 or >8.5 
 Incorrect osmolality 
o <270 mOsm or >350 mOsm 




 Detergent residues  
o Ultrasonic 
o Soaps 
o Enzymatic cleaners  
 Bacterial LPS or other endotoxin residues 
 Denatured viscoelastics 
Ocular medications 
 
 Incorrect drug concentration 
 Incorrect pH 
o <6.5 or >8.5 
 Incorrect osmolality 
o <270 mOsm or >350 mOsm 
 Vehicle with wrong pH or osmolality 
 Preservatives in drug solution 
Intraocular lenses 
 
 Polishing compounds 
 Cleaning and sterilizing compounds 
Contaminated water sources 
 
 Water baths 
 Autoclave reservoirs 





2.1.3 Traditional TASS treatment 
Steroids are often used to treat TASS. Topical, systematic, or intravitreal injected steroids are 
all used in different situations in an attempt to control TASS [9,13,15,22,90–93]. Treatment 
of mild to moderate cases of TASS with corticosteroids and close patient follow up has been 
successful [9,13,15,22,90–93].  Care must be taken when treating with steroids due to its 
known effects to increase IOP or even TASS itself [13,16,94]. Table 3 shows a summary of 
the various methods of application for the most common drugs used in the treatment of 
TASS. Most patients begin a topical treatment of steroid four times per day, which is 
increased if the symptoms do not subside [15,22,90,93]. Also, a systematic oral steroid is 
administered only if the symptoms do not clear up following a couple of days of topical 
treatment [15,22,90].  
 
Table 3: Drugs and delivery mechanisms often used in treatment of TASS 
Antibiotics Treatment Frequency 
Chloramphenicol 0.2% topical 4x daily [93] 
Polymyxin B sulphate 
0.25 MU 
topical 4x daily [93] 
Steroids   
Prednisolone acetate 
0.5-1% 
topical 4x daily [15,22,90,93] 
Prednisolone  oral 60 mg/days, 4 days post  op [15,22,90] 
 
2.2 Endophthalmitis 
Endophthalmitis is an infection of the eye that involves the vitreous cavity, aqueous humour, 
and affects surrounding tissues such as the CEC, choroid or retina.  Endophthalmitis is one of 
the most feared complications of cataract surgery because it causes severe and permanent 
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visual loss when left untreated [16,24,21]. The perceived patient quality of life is lower in 
cataract surgeries followed by endophthalmitis compared with uncomplicated cataract 
surgery, even if visual acuity is the same [95].  
Due to the severity of endophthalmitis, patients receive topical antibiotics before and after 
cataract surgery along with povidone-iodine application, both of which are shown to 
significantly reduce the occurrence of endopthalmitis [2,11,16,23,14].  This is perhaps best 
shown by the low Swedish rates of only 0.048% where intracameral cefuroxime is standard 
protocol compared to recent levels in the United States of 0.25% where it is not standard 
protocol [16]. Routinely administering drugs immediately following cataract surgery appears 
to diminish the risk of disease.  
 
2.2.1 Endophthalmitis symptoms 
Differentiating between an early onset of endophthalmitis and TASS is challenging, since 
they present many of the same symptoms [11]. Making the proper diagnosis is important, 
since misdiagnosis may lead to severe and irreversible vision loss. Endophthalmitis usually 
peaks later than TASS, between three and seven days, although it is possible to occur even 
many months following surgery. It is accompanied by pain and vitritis, which are typically 
not present in TASS [11,96,97]. The increase of IOP, due to inflammation secondary to 
TASS, is rarely seen in endophthalmitis [90]. The success of the treatment is influenced by 
causative organism, and treatment procedure [2,95]. A variety of drugs may be used based on 
the bacteria present in the infection [2,24,90,94,98], A summary of the various drugs used is 
shown below in Table 4. Due to the sensitivity of CEC, some of these drugs may be toxic to 
the CEC even at low levels and may cause clinical edema [16,99]. 
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Table 4: Drugs used in treatment of endophthalmitis 
Drug Family Drug Delivery method 
4th generation fluoroquinolone Gatafloxacin Topical 
 Moxifloxacin Topical, intracameral 
2nd generation cephalosporin Cefuroxime Intracameral 
Glycopeptide Vancomycin, ancomycin Intracameral 
Aminoglycoside  Gentamicin Topical 
N/A Povidone-iodine Topical 
 
2.3 Intraocular Lenses (IOLs) 
An IOL is an artificial polymer based lens that is placed during cataract surgery to replace the 
lens that is removed through phacoemulsion [4]. IOL material has changed little since 
poly(methyl methacrylate) (PMMA) was first introduced as an IOL in 1949 [1,100]. Despite 
over 60 years of IOL implantation, complications following cataract surgery still occur, 
including endophthalmitis and TASS as discussed above [1,101]. 
IOL material properties have been reported to influence the kind of complication that is 
more likely to arise following cataract surgery in some studies, yet not in others. According 
to in vitro studies, the attachment of infectious organism to the IOL may depend on both the 
IOL material and the organism [1], which may lead to endopthalmitis.  It has also been 
reported that organisms are more likely to attach to hydrophobic IOLs than hydrophilic IOLs 
[1].  The occurrence of endophthalmitis was not different between IOL materials in one study 
[17], while in two other studies, silicone IOLs or a hydrophobic copolymer appeared to 
increase the risk for endophthalmitis [14,102]. Thus it is difficult to conclude which material 
properties affect binding of organisms and complication rates. 
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2.4 Inflammatory inhibitors  
2.4.1 Corticosteroids 
Corticosteroids are potent anti-inflammatory agents that have been used to treat many forms 
of ocular inflammation including endophthalmitis and TASS since the 1950s [6,103,104]. 
They are able to retard the loss of endothelial tight junction proteins that are essential to 
endothelial cell function [105]. They also reduce patients’ symptoms of eye inflammation, 
swelling, heat, redness and pain when directly applied to the eye either topically or 
intracamerally [106].  
Corticosteroids have many side effects, such as induction of glaucoma, formation of 
cataracts, decreased wound healing, and increased intraocular pressure (IOP) [6,45,104].  
However, increased IOP that occurs in the week immediately following surgery may be due 
to the surgical placement of the IOL, and not the steroids themselves [104]. 
Common corticosteroids used for ocular inflammatory treatment include dexamethasone 
[106], prednisolone [6], lotepredonol etabonate [6], ciprofloxacin, triamcinolone [103], and 
recently triptolide [7,107]. Dexamethasone is the most common corticosteroid used to treat 
inflammation in the anterior segment [47,106–108]. The effects of triptolide with respect to 
CEC has not yet been investigated, but preliminary investigations suggest its ability to reduce 
inflammation in the cornea [7].Corticosteroids are commonly applied topically following 
surgery; however, patient compliance may reduce the effectiveness of topical corticosteroids 
[103].  
A challenge faced with single intracameral injection of corticosteroids is their respective 
half life in the anterior segment. Dexamethasone has a 3 h half life in vitreous fluid after 
intracameral injection [104], which is not long enough to effectively combat TASS or 
endophthalmitis following surgery without multiple injections. Triamcinolone acetate, has a 
much longer half life of 18.6 days, after a single injection; however, the toxicity and 
therapeutic efficacy over this time period has not been investigated [109]. In a drug delivery 
system, the half life of a drug requires attention, as a longer half life of a drug may increase 
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the likelihood of a toxic accumulation if release from the material is not adequately 
controlled. 
 
2.4.2 NF-κΒ pathway activation inhibitors 
NF-κΒ is activated by TNF-α and LPS during the inflammatory response on CEC 
[57,58,110]. Inhibition of this pathway may reduce CEC damage and the inflammatory 
response seen in TASS. Two novel drugs, triptolide and PPM-18, have demonstrated 
inhibition of the NF-κΒ pathways following their activation with LPS or TNF-α [7,111]. 
Triptolide, a drug developed from an herbal extract, exhibits anti-inflammatory responses 
following LPS activation of the NF-κΒ pathway with immune cells, epithelial cells, and 
fibroblasts [7]. Although no research exists on its effects on endothelial cells, its current 
efficacy warrants further exploration. PPM-18 inhibited the increase in NF-κΒ activity in 
macrophages caused by LPS stimulation [111]. The anti-inflammatory properties of triptolide 
and PPM-18 may have beneficial effects in preventing TASS and endophthalmitis. 
 
2.4.3 Protease Inhibitor 
Proteases are produced by cells in response to LPS that are activators of the immune and 
consequent inflammatory response [112–116]. This suggests that a protease inhibitor may be 
an effective method to reduce inflammation following cataract surgery in CEC. A protease 
with a specific role in the cornea is thrombin. Thrombin is a serine protease known to break 
down the gap junctions and destabilizes tight junctions reducing the barrier function of CEC 
[89]. Aprotinin, a general protease inhibitor, reduces the inflammatory response in vitro on 
HUVECs stimulated with LPS or TNF-α [54], and the production of antibodies in mice 
[116].  Despite protease’s known ability to induce inflammation in endothelial cells, and their 
abilities to reduce the barrier function in CEC, surprisingly little research exists exploring the 




2.5 Drug Delivering Methods 
The two most common methods for delivering drugs to the eye are topical application and 
intracameral injections, both of which have limitations. A drug delivery system implanted in 
the eye allows an efficient and sustained release of drug into the anterior segment, which may 
help to combat post cataract surgery infection. 
 
2.5.1 Topical and intracameral injections 
Despite topical steroid or antibiotic application inefficiency in reaching the target tissues, 
including CEC, it is routinely performed following cataract surgery [5,117,118]. Due to the 
high turnover rate of tear fluid, less than 5% to 10% of topical drug dosage applied reaches 
the corneal endothelium and anterior segment [46,47,103,119]. Also, the cornea’s structure 
of a hydrophobic epithelium followed by a hydrophilic stroma limits both water soluble and 
insoluble drugs access to the corneal endothelium [103,120]. Due to the chronic symptoms of 
uveitis, a symptom of TASS and endophthalmitis, it is necessary to maintain a therapeutic 
level of corticosteroid in the anterior chamber over time [104].  
Intracameral injection is a highly popular drug delivery method to ensure patient 
compliance and that the drug reaches the endothelium; however, it is invasive and can 
increase the risk of infection, and the drug may still have a short half life in the anterior 
segment [48,104,119]. Intracameral injection may also lead to the incidence of 
endophthalmitis, or TASS [104]. The lack of efficiency in the case of topical applications, 
and challenges or risks faced with intracameral applications could be avoided with a drug 
delivering device in the eye. 
 
2.5.2 Drug delivering devices 
Drug delivering devices allow a preventative method of administering drug following 
surgery to decrease the inflammatory response that the body is required to handle; therefore, 
reducing the appearance of the symptoms and complications of disease [121]. This is 
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important in an acute complication, such as TASS, due to its fast time of presentation. Drug 
delivering devices help increase the efficiency of the drug and improve safety and comfort 
over topical [48] or intracameral injections [103]. Subconjunctival implants allow for higher 
drug concentrations sustained over a longer time period compared to subconjunctival 
injections [103]. These benefits of drug delivering devices allow for prolonged therapeutic 
effects and automatic patient compliance to ensure the maximal benefit with the lowest cost. 
 
2.5.3 Current drug delivering devices – non IOLs 
Drug delivering devices are either biodegradable or non-biodegradable polymers 
[47,101,103,122]. Biodegradable polymer implants that have been investigated for 
intravitreal drug delivery consist primarily of a variety of polyesters [103]. These devices are 
implanted into a variety of locations within the eye depending on the targeted tissue for drug 
release. The ideal drug delivering device should offer a high level of efficacy against 
pathogens and the inflammatory response, minimize cell and protein adhesion, provide a 
sustained drug delivery over weeks or months, and produce minimal side effects [103]. 
Recently, drug-delivering polymer inserts have been developed for use intraocularly to 
increase the benefits of the corticosteroids. Two types of devices are currently used clinically 
to deliver dexamethasone [47,103]. One polymer device may be injected into sub-Tenon’s 
capsule to prevent vitreous humour inflammation and complications following eye surgery, 
including cataracts [103]. While this may be effective for many other ocular diseases, this 
injection location may not provide the necessary drug delivery to the anterior segment and 
corneal endothelium following cataract surgery.  
The second type of device is not fixed in a given place, and is free to move around within 
the vitreous of the eye. Ozurdex
TM
 (Allergan, Inc, Irvine, California) [103] and SurodexR 
(Oculex Pharmaceuticals Inc., Sunnyvale, California) [47,123] are current FDA approved 
intraocular pellets that deliver dexamethasone. These implanted drug delivering devices 
allow a more controlled release than a single intracameral injection, by allowing for a 
sustained release of drug.  When implanted at the end of a cataract surgery, they eliminate the 
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need for topical corticosteroids [47,103,123]. However, these devices are not fixed within the 
vitreous and may lead to migration of the implant to the interface between the posterior 
convexity of the IOL and the posterior capsule or lead to peripheral anterior synechiae [47]. 
This may lead to difficulties removing the implant and interference with the IOL and vision.  
Creating an IOL that is also a drug delivering device would remove the risks of a free 
floating drug delivery system, and reduce the need for a separate implant in the eye that may 
have to be removed at a later date, leading to further surgery and possible complications.   
 
2.5.4 Drug delivering devices - IOLs 
Despite an IOL always being placed during cataract surgery, few research groups have 
evaluated using the IOL itself as a drug delivery system for prevention of complications of 
endophthalmitis following cataract surgery. No drug delivery system has yet been created 
with the focus of preventing TASS. The inflammatory response seen with the physical 
trauma of cataract surgery is another focus of drug delivering IOLs. This may be achieved by 
loading the IOL with dexamethasone, NSAIDs, or matrix meatalloprotienase inhibitors 
(MMPi). Matrix metalloproteinases (MMP) are activated following the mechanical stress of 
IOL implantation, which leads to degradation of the extra cellular matrix [101]. Incorporating 
a drug into the IOL itself eliminates the need for either a separate device to be injected into 
the eye, or multiple intracameral injections. 
In attempts to reduce endophthalmitis, hydrophilic acrylic IOLs are often soaked by 
surgeons in fluoroquinolones, including norfloxacin, gatifloxacin, levofloxacin and 
moxifloxacin [122,124–127]. However, few studies have evaluated the effectiveness of this 
practice. Acrylic IOLs are able to release antibiotic at suitable levels in vitro to kill 
endophthalmitis-causing organisms [124–126]. The release of norfloxacin was maintained at 
a clinically relevant dose in situ over 114 days [122], which is long enough to combat late 
presenting endophthalmitis. An in vivo study in rabbits that compared intracameral injection 
versus an antibiotic delivering IOL determined the same efficacy against reducing infection 
[127]. This suggests that an IOL is a suitable method for delivering drug to the anterior 
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segment of the eye and preventing endopthalmitis. These effects were not studied in relation 
to endothelial toxicity and consequent possibility of TASS. 
Other IOLs are modified with NSAIDs, corticosteroids, or MMPi in an attempt to combat 
the inflammatory response occurring from trauma during cataract surgery and placement of 
the IOL [47,101,128]. The NSAID and dexamethasone loaded IOLs demonstrate an ability in 
vitro and in vivo rabbit models to reduce inflammation [47,128], which may prove beneficial 
in the treatment of TASS and reducing endophthalmitis symptoms. The NSAID loaded IOLs 
maintained a constant release for three months [128], which helps to treat longer term 
inflammation that is sometimes seen in endophthalmitis. MMPi loaded IOLs decrease in 
vitro cell viability in corneal and retinal epithelial cells, as well as stromal fibroblasts [101]. 
However, reduced cell viability suggests a toxicity that may affect other surrounding tissues, 
such as the corneal endothelium. Dexamethasone or NSAIDs appear better options than 
MMPi at reducing an inflammatory response following cataract surgery. With regards to 
reducing TASS, dexamethasone is already a recognized topical treatment and merits further 
investigation on its effects on CEC as a drug delivery system. 
Evaluation needs to be performed on drug delivering IOLs to establish the efficacy and 
toxicity of drugs in relation to the corneal endothelium. The current focus in the literature 
does not include testing of CEC either in vivo or in vitro, despite the risks to vision if 
polymers or drugs reduce their viability. The ability of these drugs to counteract cytotoxin 
and endotoxin inflammatory response should be evaluated to determine their effects at 
reducing TASS, not just general inflammation following cataract surgery. The ability of these 
compounds, especially dexamethasone, to be delivered via IOL indicates that this may be a 
successful route to explore in reducing the incidence of TASS.  
 
2.6 Role of in vitro models  
To understand the mechanism of  the inflammation response prior to human trials, as well as 
for  ethical, safety, and cost reasons, both in vivo and in vitro models are necessary [129–
133]. Due to the low occurrence of TASS, most studies are prospective, consequently dealing 
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with the clinical response as seen in vivo [9,13,22,90,134–137]. Research in endophthalmitis  
is more varied, with both in vivo prospective clinical responses 
[2,5,11,17,20,49,94,138,139,139–141], in vivo animal studies with drugs and various 
organisms [142,143], and in vitro studies investigating the effects of drugs on certain 
organisms [144–147]. In vivo clinical studies also exist for treatment of general inflammation 
following cataract surgery [45,105]. 
There are few instances in the literature where an in vivo study is created to determine the 
effects of antibiotics or preservatives used in cataract surgery on the health of the eye and 
preventing surgical complications. These studies primarily focus on the viability, density, and 
morphology of the CEC following exposure to drugs, whether in rabbit or human eyes 
[129,148–153]. However, observations on the corneal endothelium in patients are limited to 
mostly qualitative factors; limiting the conclusions that can be made to why or how a 
substance is influencing the CEC. 
Despite the necessity of in vivo animal models, there are a number of limitations to these 
studies. One of the main concerns is the ability of these models to accurately and consistently 
predict human response [98,130,133,152–155].  In vivo studies are limited in their ability to 
understand the underlying mechanisms involved with treatment responses [130]. With a 
better understanding of the mechanisms involved, drug efficacy may be better predicted, and 
more effective treatments can be developed to reduce surgical complications. In vivo models 
are much more expensive to run than in vitro studies, and as a consequence most are short 
term studies [156]. For this reason, in vitro models are used in an attempt to reduce, replace, 
or refine the number of in vivo models needed, which reduces the number of animals needed, 
and cost of the in vivo study [27,133]. 
There is a significant lack of the literature evaluating the specific effects of drugs in vitro 
on endothelial cells with an aim of reducing TASS and endophthalmitis. Some in vitro 
studies only determine release profile from materials based on reported therapeutic efficacy 
and not their toxicity or efficacy on CEC [124]. There is no pre-existing or standard model 
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currently used to help pre-screen drugs and materials based on CEC response in vitro prior to 
implantation in the cornea in vivo. 
In vitro models may allow formation of a better hypothesis related to the appropriate 
dosing schedule for a drug that would create a safe and effective method of drug treatment. 
An in vitro model allows screening of drugs and compounds quickly under a variety of 
conditions and with complex biological fluids [132]. While in vitro models also have some 
limitations due to over simplification, in vitro assays are necessary to reduce costs 
[27,133,157], and allow a quick screening of different drugs [27,133,157].  
Models for in vitro analysis with human CEC and their toxicity to drugs are rarely reported 
in the literature. There is one cell line from Bednarz (Germany) that is recurrent in the 
literature [145,146,158], and has been used by one group to evaluate the efficacy and toxicity 
of an antifungal and an antibiotic on various eye tissues in an effort to reduce infectious 
keratitis and endophthalmitis [145,146]. A primary human CEC tested the toxicity of various 
antibiotics and inflammatory inhibitors reported in the literature for application following 
cataract surgery [159]; however, dexamethasone was not among these, and further testing is 
required to determine their efficacy on these cells. The human umbilical vein endothelial cell 
(HUVEC) cell line is much more sensitive to inflammatory cytokines, especially TNF-α than 
corneal keratocytes in vitro [160]. Despite this, HUVECs are often used in vitro to study 
inflammatory responses as they show a clear response to endotoxin and cytokine stimulus 
[51,64,69,75,161,162]. The cytokines activate the NF-κB pathway for CEC and vascular 
endothelial cells in the same manner [56,163]. Dexamethasone can downregulate 
inflammatory markers following LPS stimulus on HUVECs [164], as it also appears to do in 
a prospective analysis of TASS treatment [137].  
 
2.6.1 Interspecies variation in the corneal endothelium 
Variability in CEC exists between species in cell density, response to injury, and their ability 
to replicate. These are all factors that need to be considered during in vitro and in vivo testing 
to create an appropriate model for drug and material testing. The animal chosen for the in 
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vivo and in vitro assays should be chosen based on the similarities to the human system we 
are attempting to understand [133].  
 Human CEC do not replicate in vivo. Cats and other primates’ endothelial cells also have 
minimal ability to replicate in vivo [29,31,33,40,42,165]. This is in contrast to rabbit and 
bovine CEC that replicate in vivo allowing them to repair and replenish after injury 
[41,42,166].  This allows the CEC to return to their normal shape and size several weeks 
after injury [42].  Human CEC only repair their function by cell migration and enlargement 
[41,42,166]. In cat and monkey CEC, proliferation of CEC does occur, but at a much lower 
rate than rabbit, and their cells do not fully return to the same shape and size [42]. The ability 
of proliferation of CEC seen in vivo is the largest inter-species variance in CEC, and 
represents one of the biggest challenges faced when determining the suitability of an in vitro 
animal model. This ability to reproduce may show exaggerated improvement in response to 
drugs for treatment of inflammation after cataract surgery to that seen in humans. Further 
investigation into the effects of drugs and drug delivering devices needs to be evaluated in 
endophthalmitis and TASS prevention in animals with non replicating CEC to more 
accurately mimic human CEC. Despite important differences in proliferation as discussed 
above, due to their easier availability and well known phenotype, rabbit CEC are also 
commonly used in in vivo and in vitro  models to evaluate CEC [26,27,30,85,108,142–
147,167–169].  
 
2.7 Thesis research questions 
TASS is a dangerous complication of cataract surgery on which very little research has been 
conducted outside of a clinical setting. This research project aimed to develop an in vitro 
model to help with the prevention of TASS by measuring the endothelial cell response to 
drug delivering IOLs. This research modeled TASS in a controlled laboratory setting and 
determined the effects of various treatments of drug, and drug delivering materials on 
endothelial cell viability and phenotype.  
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Specifically, this research focused on testing a novel interpenetrating network (IPN) 
biomaterial for use as an IOL. The IPN consisted of a copolymer of poly (dimethyl siloxane) 
(PDMS) and poly(N-isopropyl acrylamide) (pNIPAAm) (copolymer) that was compared 
against a control PDMS only material (polymer) for drug delivery to prevent TASS and 
endophthalmitis. The efficacy of this system was tested in vitro to allow for efficient 
screening of material and drugs to prevent TASS following cataract surgery.   
The hypothesis of this research paper was to use a novel NF-kB inhibitor, PPM-18, in 
conjunction with a drug delivering PDMS/pNIPAAm interpenetrating polymer networks as 
an intraocular lens (IOL) to successfully reduce the effects TASS and consequent vision loss. 
To determine the efficacy of PPM-18, it was compared to the cytokine inhibitor 
dexamethasone, a potent anti-inflammatory steroid already used during cataract surgery, 
along with trpitolide, another cytokine inhibitor [7,105,106,164]. An in vitro methodology 
was developed to determine changes in the viability of HUVECs via MTT assay and cell 
phenotype changes via characterization of known endothelial activation markers: ICAM-1, 
PECAM-1, VCAM-1 β1-integrin, and E-selectin, with flow cytometry. Due to the acute 






3.1 Cell Culture 
Primary HUVECs were obtained from Sciencell and grown to confluence in T-75 tissue 
culture flasks. They were grown in Endothelial Cell Media (Sciencell, Carlsbad, USA) 
containing 1% endothelial cell growth factor, 5% fetal bovine serum, and 1% penicillin-
streptomycin (ECM). All assays were performed between passages two and six. Following 
the sixth passage cell morphology visibly changed, becoming more elongated and similar in 
appearance to fibroblasts and therefore cells were discarded [52,160,162,170–174].  
 
3.2 Interpenetrating Network (IPN) Preparation 
Two different interpenetrating polymer networks were tested. A vinyl terminated 
poly(dimethylsiloxane) (PDMS) polymer (polymer) was prepared as previously described, 
with minor adjustments [175]. The material was synthesized in collaboration with Lina Liu in 
Heather Sheardown’s Lab at McMaster University. 
Briefly, the PDMS monomer was mixed with the Sylgard184 curing agent (Dow Corning 
Corp., Midland, USA), and allowed to cure for 24 h at 20
o
C. The resulting polymer films 
were rinsed in tetrahydrofruan (THF) to remove unreacted monomer and crosslinker.  
The second material was a novel hydroxyl terminated PDMS (PDMS-OH) crosslinked 
with poly(N-isopropyl acrylamide) (pNIPAAm) as previously described  [175]. The PDMS-
OH was prepared using a methacryloxypropyltriethoxysilane (MATO) crosslinker and 
tin(II)-2-ethylhexanote catalyst. This mixture was added drop-wise onto a water layer to form 
a thin film and cured for 5 days at room temperature. The PDMS-OH film was purified by a 
rinse in THF, then dried in a fumehood for 48 h, and followed by vacuum for 24 h. The 
PDMS-OH was then crosslinked with pNIPAAm. The pNIPAAm monomer (Sigma-Aldrich 
Co., Oakville, Canada) was mixed with the N,N’-methylenehis acrylamide crosslinker 
(Sigma-Aldrich Co.) and the ultraviolet (UV) sensitive initiator Xanthane (Sigma-Aldrich 
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Co). The PDMS-OH was then immersed in the mixture and allowed to equilibrate over 24 h 
at room temperature. These equilibrated polymers placed under UV for 2 h to allow the 
pNIPAAm to copolymerize with the PDMS-OH (copolymer), followed by curing for 24 h at 
room temperature. The resulting copolymer was separated from the bulk PNIMAAm and 
purified by extraction with THF for 48 h to remove unreacted monomer and crosslinker. THF 
was then removed from the material for 48 h in the fumehood followed by vacuum for 24 h.    
 Both copolymer and polymer materials formed films approximately 0.6 – 0.8 mm thick. 
Disks 5 mm in diameter were then punched out for use in experiments. These disks were 
used either in their unloaded state, or loaded with drug for experimentation. Prior to use in 
assays, the material was sterilized by exposure to UV for 20 min. 
Both materials are loaded with drugs in the same way as previously described [176]. 
Breifly, drugs were dissolved in DMSO and dry material were placed in the solution for 48 h 
at room temperature, and then dried in a fumehood and 37
o
C vacuum. Dexamethasone and 
PPM-18 samples of both polymer and copolymer were loaded. Dexamethasone samples were 
loaded to provide a cumulative release of 10 nM or 100 nM over a 4 day period. PPM-18 
samples were loaded to provide a cumulative release of 10 µM over a 4 day period.  
 
3.3 In vitro HUVECs activation and drug toxicity 
Initial toxicity testing was completed on HUVECs using known cell stimulatory mediators 
LPS (Sigma-Aldrich Co), phorbol myristate acetate (PMA) (Sigma-Aldrich Co), and TNF-α 
(R&D Systems Inc., Minneapolis, USA) to determine appropriate levels for further 
specialized testing. HUVECs were grown in either 48 well plates. 6 x 10
4
 cells were seeded 
into each well on a 48 well plate. In cases where the volume of cells and media applied to the 
plate was less than 100 µL then an approximately additional 200 µL of media were added to 
each well to ensure adequate dispersion and nutrition. The plates were then incubated for 
24 h at 37
o
C and 5% CO2 to allow cells to adhere and reach confluence. LPS (2 pg/mL to 200 
ng/mL), PMA (10, 50, 100 nM) and TNF-α (1 pg/mL – 1 mg/mL) were added the next day 
and incubated for up to four days. Medium was not replenished.  
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HUVECs response to the drugs in medium was also carried out following the protocol as 
described above with dexamethasone (10 nM) (Calbiochem, Darmstat, Germany), triptolide 
(Calbiochem), PPM-18 (10 µM) (VWR International, Mississauga, Canada; Cayman 
Chemical, Ann Arbor, USA), and aprotinin (Calbiochem). Dexamethasone concentrations 
were initially tested from 0.1 – 100 nM [7] and final comparison tests between drugs were 
done at 10 nM. Triptolide concentrations were initially tested at 1-30 nM [7] and final runs 
were completed at 3 nM. HUVECs were incubated first with only these concentrations. 
PPM-18 concentrations were initially tested from 0.1 – 30 µM [111], with final comparison 
tests done at 10 µM.   
 
3.4 HUVECs interaction with biomaterials 
HUVECs were grown in either 48 or 24 well plates, depending on the cell count following 
detachment from the culture flask. 6 x 10
4
 cells were seeded into each well on a 48 well plate 
and 12 x 10
4
 cells per well in a 24 well plate. The plates were incubated for 24 hr at 37
o
C and 
5% CO2 to allow cells to adhere and reach confluence.  Small discs of IPNs materials were 
either placed gently on the cell monolayer (in a 48 well plate containing 250 µL of fresh 
ECM), or in a 24 well plate within a hanging well insert and 1 mL of ECM. These are 
illustrated in Figure 6. 
 
Figure 6: Drug delivery in vitro model in either a 24 or 48 well plate 
The number of discs was adjusted to ensure appropriate drug release.  The release for 
dexamethasone IPN was 10 nM or 100 nM over 4 days, and for PPM-18 loaded IPN was 
10 µm or 30 µM over 4 days.  





3.5 Viability assay 
Drug toxicity and material biocompatibility were assessed by measuring viability using the 
MTT assay. MTT (3-( 4,5-dimethylthiazol-2yl)-2,5diphenyl tetrazolium bromide) is a 
tetrazolium salt that measures the activity of dehydrogenase enzymes, only found in living 
cells, through a rapid colorimetric assay that was initially developed by Mosmann in 1983 
[177].   
The protocol followed for MTT testing on HUVECs was modified from one previously 
described [178].  MTT was dissolved in ECM at a ratio of 0.5 mg/mL. The solution was 
vortexed and warmed to 37
o
C to help facilitate complete dissolving of the MTT, and was 
then sterile filtered.   
Before adding the MTT solution to the cell monolayer in a 48 well place, supernatant in 
each well was aspirated, and rinsed with PBS. 100 µL of MTT solution was added to each 
well. If too much MTT solution was added, the cells would not remain adherent to the 
bottom of the plate. The plates were incubated for 12-24 h at 37
o
C and 5% CO2. During 
incubation, a dark blue formazan product was produced by the mitochondria of living cells 
cleaving the MTT [177]. After the incubation period, solution was aspirated off the plates 
and 200 µL of DMSO was added to each well (dissolving the formazan crystals). The 
dissolved solution was transferred to a 96-well plate and read on an absorbance reader at 
595 nm wavelength, ensuring no final measurement was above 2.0. Plates were read within 
1 h of adding the DMSO. The absorbance was directly proportional to the number of living 
cells, with more absorbance indicating a greater number of living cells [177]. The final 
measurements were recorded and analyzed on the computer as a percentage change from 
control.  
3.6 Flow Cytometry 
Flow cytometry is a common technique to assess cell population, determine cell size, and 
characterize cell phenotype. A laser of a specific wavelength is aimed at a stream of 
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hydrodynamic focused fluid, so only a single cell is passed through the beam at a time. This 
is crucial to allow for accurate collection of data. The cells may pass through the beam at 
thousands per second (Figure 7).  
 
Figure 7: BD FACSCalibur optical path configuration. Figure taken from BD 
FACSCalibur brochure which demonstrates its basic set up, and is the same flow cytometer 
used in this research.  
 
As the cell passes through the laser there is both forward and side scatter. Forward scatter 
determines cell and particulate size. Side scatter is caused by granularity and complexity 
within the cell, which when combined with the forward scatter data can isolate different cell 




Figure 8: Flow cytometry plot for forward scatter (FSC) vs. side scatter (SSC). The 
forward scatter indicates particle size, and side indicates granularity. This plot is gated on the 
HUVEC population. 
 
As these cells were incubated with fluorescent marker, the fluorescence of these cells is 
emitted in proportion to the amount of marker attached to cell, which are read on separate 
channels. There were three fluorescence markers used in our assays. Fluorescein 
isothiocyanate (FITC) is the green fluorescence marker most commonly used. It is the major 
derivative of fluorescein. FITC has an excitation of 495 nm and an emission at 521 nm. 
Phycoerythrin (PE; orange fluorescence marker) can be excited at 495 nm, but also at around 
545/566 nm.  The emission peak of 575 nm allows it to be used simultaneously with FITC as 
a marker on cells. Phycoerytrin-cyanine dye conjugate (PE-Cy5; red fluorescence marker) 
has an excitation of 488 nm and an emission at 667 nm, allowing it to be compatible with 
both FITC and PE conjugated antibodies. These create further population graphs of the 
comparison of the channels over time, such as FITC vs. PE (Figure 9A), as well as a 




Figure 9: Example of typical fluorescent data plots in flow cytometry. (A) Fluorescent 
intensity of FITC markers (FL1) vs. intensity of PE markers (FL2) on untreated HUVECs 
positive for the PE marker and negative for FITC marker. (B) Fluorescent intensity histogram 
for PE channel indicating presence of PE marker on cells. 
 
3.6.1 Flow Cytometry Protocol 
To ensure an adequate number of cells for flow cytometry, samples ran in 48-well plates 
were run in duplicate and pooled.  
Following interactions with materials or drugs, cell samples were processed for flow 
cytometry. HUVECs were removed from the wells with TrypLExpress (55 min at 37
o
C, 
Invitrogen, Burlington, Ontario, Canada). Cells were washed and resuspended in 
DMEM/FBS. Small aliquots (30uL) of HUVECs, diluted in DMEM-FBS, were incubated for 
1 h at 4
o
C with saturating concentration of fluorescently-labeled antibodies against ICAM-1, 
Integrin-β1, E-selectin, CD44, and VCAM-1. Samples were then diluted in Hepes Tyrode 
Buffer, fixed in 1% paraformaldehyde (final concentration) and analysed by flow cytometry 
within 5 days.   
To determine if exposure to drug or biomaterial led to cell apoptosis or necrosis, caspase 
activation and propidium iodide (PI) uptake on adherent cells was studied. HUVECs were 
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removed from the wells as described above. Small aliquots of HUVECs, diluted in 
DMEM/FBS, were incubated with a fluorescently-labelled pan caspase inhibitor (FITC-
VAD-FMK, Calbiochem, San Diego, California) for 1 h at 37
o
C. Samples were washed and 
resuspended in wash buffer, 1 mL of PI was added to each tube and samples were analyzed 
immediately by flow cytometry. Table 5 below summarizes the assays performed on 
HUVECs following incubations with material/drug. All antibodies were purchased from BD 
Diagnostics, Canada. The samples were stored at 4C and analyzed within 5 days with the 




Table 5: Selected CEC membrane receptors or intracellular stains and their measured 
response. 
Membrane receptor 
or intracellular stain 
Functions 
ICAM-1 endothelial cell adhesion molecule [64–69] 
β1-Integrin cell adhesion molecule present in all human cells [72] 
PECAM-1 endothelial cell adhesion and signaling receptor [75,76] 
CD44 transmembrane endothelium glycoprotein adhesion 
molecule [78,79] 
E-selectin endothelial cell adhesion molecule [67,69] 
VCAM-1 endothelial cell adhesion molecule [64,68] 
PI evaluates cell necrotic response [179] 
VAD-FMK measures caspase activation 
 
3.6.2 Flow cytometry acquisition/analysis 
All membrane receptors and caspase samples were acquired on a BD  FACSCalibur flow 
cytometer using CELLQuest Software. Appropriate isotype controls were used with each 
experiment. Analysis was also performed using FACSExpress post data acquisition.   
 
3.7 Statistical analysis 
All results are reported as means ± standard deviation (SD). To evaluate the significance of 
the differences in cell viability and cell activation, an ANOVA was carried out followed by a 
multiple pair-wise comparisons using the Tukey HSD  test using Statistica V10 (StatSoft, 
Tulsa, OK, USA).  Samples were compared to cells grown without material or drug.  A p 





4.1 HUVECs response to soluble drug 
4.1.1 Cell Viability following exposure to soluble drug 
4.1.1.1 MTT response to soluble drugs at varying concentrations 
Testing of the viability of soluble drugs through MTT was the first test performed. This test 
provided a reliable initial screening for the toxicity of drugs to allow us to choose appropriate 
concentrations to continue with further analysis on HUVECs response.  
Dexamethasone showed no significant differences for viability between control and 
treatments following a 24 h application of drug in media. These results are summarized in 
Table 6.  
 
Table 6: HUVECs’ viability after 24 h to dexamethasone. HUVECs were exposed to 
dexamethasone (0.01-1000 nm) for 24 h and viability was assessed by MTT and compared to 
HUVECs in ECM. n=4. 
Treatment 
(nM) 
% Viability  










PPM18 showed no significant differences in cell viability between control and drug 
treatments after 24 h exposure (Table 7). The PPM-18 used in these tests was purchased from 
VWR International.  
 
Table 7: HUVECs’ viability after 24 h exposure to PPM-18. HUVECs were exposed to 
PPM-18 (0.1 - 30 µm) for 24 h and viability was assessed by MTT and compared to 













As shown in Figure 10, triptolide showed a significant decrease (p<0.01) in viability for 




Figure 10: Response of HUVECs after 24 h exposure to triptolide. HUVECs were 
exposed to triptolide (0 - 300 nM) for 24 h and viability was assessed by MTT and compared 
to HUVECs in ECM.  n=4. 
*statistically significant from control (p<0.05) 
#statistically significant from concentrations 30 nM and below (p<0.05) 
 
These viability results from the MTT assays indicated that dexamethasone (0.01-1000 nM) 
and PPM-18 (0.01-1000 nM) were non toxic at the levels tested, while triptolide was non-
toxic at levels of 30 nM and lower. Based on these results, further testing was performed to 


























* #  * # 
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4.1.2 Change in cellular phenotype in response to soluble drug 
Drug concentrations determined to be non-toxic were identified, and the changes in 
HUVEC’s cellular phenotype in response to soluble drug was assessed. Exposure to 
dexamethasone (10 nM), triptolide (3 nM), aprotinin (20 µM), and PPM-18 (10 µM) showed 
no significant up or down regulation of the membrane receptors tested. The cellular 
responses observed for ICAM-1, E-Selectin, CD44, β1-integrin and PECAM-1 are shown in 
Table 8. 
 
Table 8: Phenotype changes to soluble drugs after 24 h. HUVECs were exposed to 
dexamethasone (10 nM), triptolide (3 nM), aprotinin (20 µM), and PPM-18 (10 µM) for 24 h 
and analyzed by flow cytometry.  For cell activation markers ICAM-1, E-selectin, CD44, 1-
integrin, and PECAM-1, activation is expressed relative to control cells, HUVECs in ECM. 
n=3. 

















117±21 103±3 104±11 103±5 99±9 
Triptolide (3 nM) 141±19 105±2 104±2 105±4 99±4 
Aprotinin (20 M) 128±32 100±19 99±15 90±11  
PPM-18 (10 M) 129±36 113±9 105±2 109±4 99±13 
 
As none of the drugs induce a significant difference in expression for any of the activation 
markers, we were able to continue to test these drugs against their ability to regulate LPS 
response and investigate their loading into polymer and copolymer materials.  
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4.2 HUVECs response to LPS  
To develop an in vitro model of inflammation of TASS, the ability of LPS to activate 
HUVECs was assessed. Through activation of HUVECs to LPS, we aimed to measure a 
given drugs’ ability to reduce the inflammatory response of LPS on HUVECs. 
 
4.2.1 Cell Viability following exposure to LPS 
MTT viability testing was completed with LPS at concentrations ranging from 2 pg/mL to 
200 ng/mL. There were no significant differences between any of the tested levels for LPS. 
The values are shown below in Table 9. 
 
Table 9: HUVECs’ viability following 24 h exposure to LPS. HUVECs were exposed to 
LPS (2 pg/mL to 200 ng/mL) for 24 h; viability was assessed by MTT and compared to 





Control (0.0) 102 ±3 
200.0 92±9 
20.0 99 ±18 
2.0 101±17 
0.2 101±13 
2.0 x10-2 99 ±24 
2.0 x10-3 108 ±18 
2.0 x10-4 105 ±12 
2.0 x10-5 105 ±7 




Using flow cytometry, PI was used to label necrotic cells in a given treatment sample.  The 
results for HUVECs with and without LPS stimulation (100 ng/mL) are reported in Table 10. 
No significant difference was observed between unstimulated HUVECs and LPS stimulated 
cells, suggesting that LPS did not induce a necrotic or apoptotic response in cells. 
 
Table 10: Necrosis in HUVECs following 4 day exposure to LPS. HUVECs were exposed 
to LPS (100 ng/mL) for 4 days and analyzed by flow cytrometry. Control cells are HUVEC 
grown in ECM alone. n=7. 





Control 82±9 14±7 
LPS 83±10 13±7 
 
4.2.2 Change in cellular phenotype in response to LPS 
Cellular phenotype changes were evaluated in response to LPS (0.2 and 2.0 µg/mL) prior to 
testing drug and material response to determine LPS suitability as an inflammatory stimulus 
on HUVECs.  Tests were performed at 48 h to provide insight into the response over a 
relevant TASS time point. ICAM-1, E-selectin, β1-integrin, CD44, and PECAM-1 were all 
evaluated. The only significant differences found were between LPS (2 µg/mL) and control 
for ICAM-1 and E-selectin (p<0.05). All values are shown in Table 11. The upregulation 






Table 11: Relative response of HUVECs to 48 h exposure to LPS. HUVEC were exposed 
to LPS (0.2 µg/mL and 2.0 µg/mL) for 48 h and analyzed by flow cytometry. For cell 
activation markers, ICAM-1, E-selectin, CD44, 1-integrin, and PECAM-1, activation is 















Control 100±0 100±0 100±0 100±0 100±0 
LPS 
(0.2 µg/mL) 
426±56 105±2 115±23 134±21 97±8 
LPS  
(2.0 µg/mL) 
*710±357 *134±23 126±33 134±26 92±6 
*significant difference from control (p<0.05) 
 
Since the literature indicated that a peak in E-selectin expression on cells may occur at 
shorter times, a small investigative experiment was performed at various time points. As seen 
in Figure 11, there appears to be a peak expression of E-selectin at 6 h that is then reduced by 




Figure 11: Response of HUVECs to LPS between 3 h and 48 h. HUVECs were exposed to 
LPS (0.2 µg/mL and 2.0 µg/mL) for 48 h and evaluated at 3 h, 6 h, 12 h, 24 h, and 48 h for 
E-selectin expression by flow cytometry.  E-selectin expression is reported relative to control 
cells, HUVECs in ECM.  n=1 for 3 h-12 h; n=3 for 24 h-48 h.  
 
4.3 HUVECs response to LPS and soluble drugs 
The ability of soluble drugs to reduce cytokine activation of cells was measured based on non 
toxic levels of drugs, as discussed in 4.1 and those found in the literature. All tests were 
carried out with LPS stimulation at 100 ng/mL. Although this level was not tested for 
upregulation of markers, further review of the literature indicated this was an appropriate 
level to see both cellular response and changes in cell phenotype. 
The effects of drugs on LPS stimulated HUVECs were first measured after a 24 h time 
point. As shown in Figure 12, LPS with or without drugs upregulated ICAM-1 expression. 

























0.2 µg/mL LPS 
2.0 µg/mL LPS 
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PPM-18 (10 µM) were all significantly different (p<0.01) from unstimulated HUVECs. 
There were no significant differences between any of the stimulated cell treatments, 
suggesting that the presence of drugs had no effect on ICAM-1 upregulation induced by LPS. 
 
  
Figure 12: ICAM-1 upregulation in HUVEC after 24 h exposure to LPS and LPS with 
dexamethasone, triptolide, aprotinin, and PPM-18. HUVECs were exposed to LPS, LPS 
and dexamethasone (10 nM), LPS and triptolide (3 nM), LPS and aprotinin (20 µM), or LPS 
and PPM-18 (10 µM) for 24 h and analysed by flow cytometry.  ICAM-1 expression is 
reported relative to control cells, HUVECs in ECM. n=3 except for LPS n=4. 
*statistically significant from control (p<0.01) 
# statistically significant from control (p<0.001).  
 
Dexamethasone was then tested at higher concentrations to ensure that its inability to down 
regulate LPS stimulus was not due to an inappropriate drug concentration. After 24 h, there 
was a significant difference in ICAM-1 upregulation (p<0.001) between the unstimulated 




























these levels of dexamethasone, while non-toxic to cells were not able to reduce the 
upregulation in ICAM-1 caused by LPS. 
 
 
Figure 13: ICAM-1 upregulation in HUVECs following exposure to dexamethasone 
with and without LPS for 24 h. HUVECs were exposed to varying concentrations of 
dexamethasone (10 nm - 10 µm) with and without LPS (100 ng/mL) for 24 h and analysed 
with flow cytometry.  ICAM-1 expression is reported relative to control cells, HUVECs in 
ECM. n=3; LPS n=2. 
*statistically significant from control (p<0.001) 
# statistically significant from cells exposed to drug only (p<0.001)  
 
To determine if dexamethasone required a longer time to exert its effects on LPS-
stimulated cells, a 4 day time point was assessed. After 4 days, the significant difference in 
ICAM-1 expression (p<0.001) between unstimulated cells and all LPS stimulated cells, with 
or without drug, was still present.  There was also a significant difference between all LPS 
stimulated with drugs cells and cells exposed to drug only, further confirming our results that 


















































Figure 14: Response of HUVECs to varying concentrations of dexamethasone with and 
without LPS for ICAM-1 at 4 days. HUVECs were exposed to varying concentrations of 
dexamethasone (10 nm - 10 µm) with and without LPS (100 ng/mL) for 4 days and analysed 
with flow cytometry. ICAM-1 expression is reported relative to control cells, HUVECs in 
ECM.  n=3; LPS n=2. 
*statistically significant from control (p<0.001) 
# statistically significant from cells exposed to drug only (p<0.001)  
 
As seen in Table 12, the ability of varying concentrations of dexamethasone to affect and 
reduce LPS-stimulated expression of VCAM-1, β1-integrin, E-selectin and CD44 on 

















































Table 12: Response of HUVECs to varying concentrations of dexamethasone with and without LPS at 24 h and 4 days. 
HUVECs were exposed to varying concentrations of dexamethasone (10 nM - 10 µM) with and without LPS (100 ng/mL) for 24 h 
and 4 days and analysed with flow cytometry relative to control.  For cell activation markers, VCAM-1, CD44, E-selectin, and 1-
integrin, activation is expressed relative to control cells, HUVECs in ECM. n=3. 








24 h 4 days 24 h 4 days 24 h 4 days 24 h 4 days 
Control  
(no dex) 
100±0 100±0 100±0 100±0 100±0 100±0.1 100±0 100±0 
LPS 91±32 111±26 110±1 121±9 93±8 99±8 105±9 96±5 
Dex 10nM 130±68 90±2 122±14 104±4 105±26 88±6 110±8 93±3 
Dex 100nM 89±24 101±7 110±2 101±3 89±12 93±8 101±5 93±5 
Dex 1µM 115±24 92±2 99±9 102±78 97±20 91±10 102±7 97±5 
Dex 10µM 104±45 97.5±5 107±5 104±16 97±17 98±17 102±5 99±6 
LPS + Dex 
10nM 
115±55 *137±28 104±11 136±39 102.±7 100±15 99±9 112±20 
LPS + Dex 
100nM 
170±54 *138±21 102±14 137±33 99±9 103±9 99±11 106±14 
LPS + Dex 
1µM 
108±19 *136±16 98±15 123±28 101±15 93±9 143±72 103±9 
LPS + Dex 
10µM 
173±87 119±6 95±18 132±22 106±20 107±8 89±11 108±14 
#




As mentioned previously, PPM-18 had sourcing challenges after receiving the initial 
supply from VWR, with which the preliminary viability tests had been carried out. An 
alternative supplier of PPM-18 was found (Cayman Chemical, Ann Arbor, USA), and this 
PPM-18 was used for the remainder of the tests.  PPM-18 applied to HUVECs appeared to 
cause changes in the cellular phenotype as measured with ICAM-1, VCAM-1 E-selectin, 
CD44, and β1-integrin. However, after statistical analysis, the presence PPM-18 in cell 
medium did not significantly upregulate or downregulate ICAM-1 response (Table 13). 
VCAM-1 results are also shown in Table 13, and despite an upregulation by both PPM-18 
alone and with LPS, the only significant differences are between PPM-18 at 30 µM with LPS 
and the unstimulated HUVECs (p<0.01).  
 
Table 13: Response of HUVECs after 4 day exposure to PPM-18 stimulated cells with 
or without LPS. HUVECs were exposed to PPM-18 (10 µM and 30 µM) with or without 
LPS (100 ng/mL) for 4 days and analysed with flow cytometry. ICAM-1 and VCAM-1 
expression are reported relative to control cells, HUVECs in ECM.  n=3. 




Control 100 ±0 100±0 
LPS 166 ±47 96±17 
PPM-18 (10 µM) 90 ±7 273±28 
PPM-18 (30 µM) 104 ±27 265±47 
LPS + PPM-18 (10 µM) 111 ±27 302±48 
LPS + PPM-18 (30 µM) 101 ±21 *381±168 
* significant difference from control and LPS (p<0.01)  
 
For E-selectin, there were significant differences in the response from unstimulated 
HUVECs and LPS only cells compared to PPM-18 (10 µM) exposed HUVECs (Figure 15). 
The response to LPS with PPM-18 (10 µM and 30 µM) was also significantly upregulated 
 
 51 
compared to unstimulated HUVECs and LPS only cells (p<0.05). This response suggested 
that PPM-18 stimulated the expression in E-selectin in cells independently of LPS.  
 
 
Figure 15: E-selectin expression on HUVECs after 4 day exposure to PPM-18 
stimulated cells with or without LPS.  HUVECs were exposed to PPM-18 (10 µM and 30 
µM) with or without LPS (100 ng/mL) for 4 days and analysed with flow cytometry. E-
selectin expression is reported relative to control cells, HUVECs in ECM.  n=3. 
* significant difference from control and LPS (p<0.05)  
 
When compared to HUVECs and LPS stimulated cells, CD44 was significantly 
upregulated (p<0.05) in response to PPM-18 (10 µM and 30 µM) both with and without LPS 








































Figure 16: CD44 expression in HUVECs after 4 day exposure to PPM-18 stimulated 
cells with or without LPS.  HUVECs were exposed to PPM-18 (10 µM and 30 µM) with or 
without LPS (100 ng/mL) for 4 days and analysed with flow cytometry. CD44 expression is 
reported relative to control cells, HUVECs in ECM.  n=3. 
* significant difference from control and LPS (p < 0.05)  
 
As illustrated in Figure 17, in the presence of PPM-18 with or without LPS, β1-integrin 
was significantly downregulated when compared to unstimulated HUVECs or LPS 
stimulated cells (p<0.05). This downregulation was an unexpected response and further 


























Figure 17: β1-integrin expression on HUVECs after 4 day exposure to PPM-18 
stimulated cells with or without LPS. HUVECs were exposed to PPM-18 (10 µM and 30 
µM) with or without LPS (100 ng/mL) for 4 days and analysed with flow cytometry. β1 
integrin expression is reported relative to control cells, HUVECs in ECM.  n=2. 
* significant difference from control (p < 0.01) 
# significant difference from LPS (p<0.05) 
+ significant difference from LPS+PMM-18 (10 µM)  
 
4.4 Biocompatibility of polymer and copolymer with and without drug loading 
The effects of the polymer and copolymer were evaluated primarily through changes in 
cellular phenotype. The cell scatter plots, which report the size and granularity of the 
particles passing through the flow cytometer, showed significant changes in cell scatter 
following interaction with drug loaded material. Some materials underwent the drug loading 
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polymers.” Figure 18 illustrates some of the commonly observed changes in the scatter plots. 
Most samples could be considered as having scatter plots similar to untreated cells as shown 
in Figure 18.A. Samples containing PPM-18 loaded material showed different cell scatter 
characteristics (Figure 18.B), where both cell size and granularity were reduced. 
Consequently, the gating region was moved slightly to include the analysis of a larger 
population of events. Typically, the change in scatter characteristics did not reduce the 
number of events. However, increasing the levels of dexamethasone in order to see a greater 
cellular response resulted in lower event number as well as a greatly reduced scatter as 
shown in plot Figure 18.C. When LPS was added to the 100 ng/mL samples of 
dexamethasone copolymer, an increase in event size was observed (see Figure 18.D). Due to 
the odd shapes and low event counts obtained with dexamethasone at 100 ng/mL, results 










Figure 18: Scatter plots showing cell shape response to various polymer and copolymer 
treatments after 4 days exposure to HUVECs. (A) Typical cell size distribution and region 
used to gate on HUVECs. These are untreated control cells. (B) Cell scatter in response to 
10µM PPM-18 polymer. This is a typical cell scatter change seen in response to PPM-18 
loaded into a material or on its own. Region was moved to include more cells. (C) 100 nM 







Viability of HUVECs in response to the polymer and copolymer, both unloaded and mock 
loaded, were evaluated using the percentage of necrotic cells stained with PI. There was no 
difference seen between treatment types as shown in Table 14, suggesting that the materials 
were not toxic on their own. 
 
Table 14: HUVECs’ necrosis following 4 days exposure to polymer and copolymer, 
unloaded or mock loaded. HUVECs were exposed to material treatment and analysed by 
flow cytometry. Necrotic cells were identified by PI uptake.  n=4. 






Control 82±9 15±8 
Polymer 83±9 15±8 
Copolymer 83±10 14±8 
Polymer mock loaded 85±8 13±5 
Copolymer mock loaded 82±9 14±5 
 
Initial evaluation of HUVECs’ response to both materials for any of the measured markers 
(ICAM-1, VCAM-1, or CD44) showed that there was no significant difference between 
HUVECs with no material or those that were exposed to the material in media over 4 days. 
No significant difference was seen in HUVECs exposed to materials that had undergone the 
drug loading process, but had no drug added to the drug loading solvent. The values are 






Table 15: Response of HUVEC after 4 day exposure to polymer and copolymer, 
unloaded or mock loaded. HUVECs were incubated with materials for 4 days and analysed 
with flow cytometry.  ICAM-1, VCAM-1 and CD44 expression are reported relative to 
expression on control cells, HUVECs in ECM. n=4, polymer mock loaded n=3, copolymer 
mock loaded n=2. 









Control - No Material 100 ±0 100 ±0 100 ±0 
Polymer 122 ±10 127±43 104±10 
Copolymer 111±17 111±22 97 ±7 
Polymer mock loaded 145±42 114±28 101±11 
Copolymer mock loaded 125±13 141±50 102 ±10 
 
 
The drug loaded materials were compared against each other and the non drug delivering 
materials in Table 16. Large variability in the ICAM-1 expression in HUVECs was seen in 
response to the PPM-18 copolymer samples. Two batches of polymer sample were tested 
with improvements made to the polymerization process to reduce contamination between 










Table 16: ICAM-1 response in HUVECs after 4 day exposure to polymer and 
copolymer materials, unloaded, mock loaded or loaded with either dexamethasone or 
PPM-18. HUVECs were exposed to soluble dexamethasone (10 nM), soluble PPM-18 
(10 µM), and polymer or copolymer, either unloaded, mock loaded or loaded with either 
dexamethasone (10 nM) or PPM-18 (10 µM) for 4 days, and analysed by flow cytometry. 
ICAM-1 expression is reported relative to expression on control cells, HUVECs in ECM. 









Polymer mock loaded 229±172 
Copolymer mock loaded 195±218 
Dex polymer 109±13 
Dex copolymer 108±6 
PPM18 polymer 131±43 
PPM18 copolymer, batch 1 1639±930 
PPM18 copolymer, batch 2 104±8 
 
With respect to VCAM-1, there was a significant difference between PPM18 loaded 
polymer and copolymer and all other samples as seen in Figure 19. A similar observation 
could be made for CD44 whereby PPM-18 loaded polymer and copolymer was significantly 
different from all other samples as indicated in Figure 20 (p<0.01). The observed 
upregulation by PPM-18 suggested that PPM-18 induced an inflammatory response that was 
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independent of the material or the loading process. Both VCAM-1 and CD44 were not 
influenced by the batch of the polymer, so results were pooled. 
 
 
Figure 19: VCAM-1 expression on HUVECs after 4 day exposure to polymer and 
copolymer materials with various treatments and dexamethasone (10 nM) or PPM-18 
(10 µM). HUVECs were exposed to soluble dexamethasone (10 nM), soluble PPM-18 
(10 µM), and polymer or copolymer either unloaded, mock loaded, or loaded with either 
dexamethasone (10 nM) or PPM-18 (10 µM) for 4 days, and analysed by flow cytometry.  
VCAM-1 expression is reported relative to its expression on control cells, HUVECs in ECM. 
n=4; soluble drug, Dex copolymer and PPM-18 polymer n=3.  
* significant difference from control, polymer unloaded and loaded, polymer loaded, and 
dexamethasone loaded and unloaded polymer and copolymer (p<0.001) 



























Figure 20: CD44 expression on HUVECs after 4 day exposure to polymer and 
copolymer materials with various treatments and dexamethasone (10 nM) or PPM-18 
(10 µM). HUVECs were exposed to polymer and copolymer, unloaded, mock loaded or 
loaded with either dexamethasone (10 nM) or PPM-18 (10 µM) for 4 days, and analysed by 
flow cytometry. VCAM-1 expression is reported relative to its expression on control cells, 
HUVECs in ECM. n=4; soluble drugs, and PPM-18 polymer n=3.  
* significant difference from control (p<0.05) 
# significant difference from  unloaded copolymer (p<0.05)  
^ significant difference from mock loaded polymer and copolymer (p<0.05) 
+ significant difference from dexamethasone copolymer (p<0.01) 
 
4.4.1 HUVECs viability response to materials 
The cellular viability response of HUVECs to materials was characterized both with MTT 
and PI. Due to lack of materials and time constraints, the MTT testing was only performed 
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response to exposure to either PPM-18 loaded materials, both after 24 h and 4 days (Figure 
21). These materials were all from the second batch of polymer synthesis. This was expected 
given the previously observed upregulation of activation markers VCAM-1 and CD44. 
Soluble drug values were taken from the same assays as used to determine material viability. 
PPM-18 was from a different source than used for the initial viability assays. Due to limited 
number of cells, soluble dexamethasone was unable to be tested at 4 days, along with the 
loaded materials and soluble PPM-18. 
 
  
Figure 21: HUVECs’ viability after 24 h exposure to dexamethasone and PPM-18: 
soluble, and loaded polymer or copolymer. HUVECs were exposed to dexamethasone (10 
µM) and PPM-18 loaded into polymer and copolymer materials for 24 h and 4 days. 
Viability was assessed by MTT and compared to control, HUVECs only in ECM. Due to 
































As an alternate method to assess viability, PI was used to test for the effects of materials on 
cellular viability after 4 days. Table 17 shows an almost complete necrotic response to PPM-
18 loaded polymers. Only PPM-18 loaded polymer and copolymer showed significant 
differences between their level of necrotic cells and that of all other treatments’ (p<0.001). 
These observations support the results seen in the MTT assay showing PPM-18 loaded 
material leading to a decrease in HUVECs’ viability. The material response is compared to 





Table 17: Population of HUVEC necrotic cells after 4 day exposure to soluble 
dexamethasone or PPM-18, and polymer and copolymer, unloaded or mock loaded, as 
well as dexamethasone or PPM-18 loaded polymer and copolymer. HUVECs were 
exposed to soluble dexamethasone (10 nM), soluble PPM-18 (10 µM), and polymer and 
copolymer, unloaded or mock loaded, as well as dexamethasone (10 nM) or PPM-18 (10 
µM) loaded polymer or copolymer for 4 days and analyzed by flow cytometry. Soluble 
dexamethasone and dexamethasone loaded polymer n = 1; PPM-18 polymer n=3; Soluble 
PPM-18 and PPM-18 copolymer n=2; all others n=4. 
Treatment Live Cells (%) 
(mean±SD) 
Necrotic Cells (%) 
(mean±SD) 
Control 81±8 11±5 
Dexamethasone  831 131 
PPM-18 29±401 69±401 
Polymer 83±9 15±8 
Copolymer 83±10 14±8 
Polymer mock loaded 84±8 13±5 
Copolymer mock loaded 82±9 14±5 
Dexamethasone polymer 85 10 
Dexamethasone copolymer 85±5 12±4 
PPM-18 polymer 1±1 *100±1 
PPM-18 copolymer 2±2 * 80±312 
* significant difference from control, unloaded polymer, loaded polymer and copolymer, and 
dexamethasone polymer and copolymer (p<0.001) 
 
 
                                                 
1
 See next page for detailed results on toxicity of soluble drug 
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4.4.1.1 Cellular phenotype viability response  
Exploratory experiments were performed following material testing, to further understand 
cell response to dexamethasone and PPM-18. Cell death and programmed cell death was 
assessed by flow cytometry with dexamethasone and PPM-18. To illustrate the toxicity of 
PPM-18, as compared to dexamethasone and control, scatter plots from all flow cytometry 
analysis are provided in Figure 22 and Figure 23. The plots indicate cellular activity by 
quadrant based on the uptake of PI or caspase activation (FITC-VAD-FMK).  
These flow cytometry tests with caspase and PI were performed on cells that had been 
exposed to PPM-18 purchased from Cayman Chemical, a different supplier than the one used 
in the preliminary MTT viability testing where no decrease in cellular viability had been 
observed. With these later tests, there is clear indication that PPM-18 induced a severe 
necrotic response in HUVECs.  
The first trial is shown in Figure 22. In Figure 22.A, showing unstimulated HUVECs after 
a 4 day culture, the majority of cells are live; however, in Figure 22.B and C, following 
treatment with PPM-18 (10 µM and 30 µM, respectively) the entire population of cells has 
undergone necrosis. Dexamethasone does not indicate a drastic increase from unstimulated 
HUVECs in necrotic or apoptotic cells. Upon repeating the experiment with PPM-18 (10 µM 
and 30 µM, Figure 23.B and C respectively), there is very little or no increase in necrosis or 
necrosis and apoptosis from unstimulated HUVECs (Figure 23.A). PI and caspase activation 
are very time dependent in measurement. The variations in the necrosis levels from those in 





Figure 22: Plots illustrating necrosis and apoptosis levels in HUVECs following 4 day 
treatment for first assay performed with PPM-18 (10 µM and 30 µM) and 
dexamethasone (10 nM). The plots indicate percentage cellular activity by quadrant. The 
upper left indicates cells are necrotic, lower left is live cells, upper right shows necrotic and 
apoptotic cells, while lower left indicates apoptosis. Live cells were identified based on their 
exclusion of PI and FITC-VAD-FMK.  Necrotic cells were identified by their uptake of PI. 
(A) Control, untreated HUVECs. (B) PPM-18 (10 µM) treated HUVECs. (C) PPM-18 (30 
µM) treated HUVECs. (D) Dexamethasone (10 nM) treated HUVECs. HUVECs were 
























Figure 23: Plots illustrating necrosis and apoptosis levels in HUVECs following second 
4 day treatment assays performed with PPM-18 (10 µM and 30 µM). The plots indicate 
percentage cellular activity by quadrant. The upper left indicates cells are necrotic, lower 
left is live cells, upper right shows necrotic and apoptotic cells, while lower left indicates 
apoptosis. Live cells were identified based on their exclusion of PI and FITC-VAD-FMK.  
Necrotic cells were identified by their uptake of PI. (A) Control, untreated HUVECs. (B) 
PPM-18 (10 µM) treated HUVECs. (C) PPM-18 (30 µM) treated HUVECs. HUVECs were 



















4.4.2 HUVECs’ response to DMSO 
Both dexamethasone and PPM-18 were dissolved in the organic solvent DMSO. Although 
residual levels of DMSO should remain low in media solution, the effects of low level 
DMSO exposure to HUVECs was characterized to understand the possible cellular response 
observed when drug, or drug loaded material was incubated with HUVECs. The relative 
concentrations of DMSO in ECM when incubated with HUVECs are shown in Table 18 for 
dexamethasone (10 nM, 100 nM, and 10 µM) and PPM (10 µM and 30 µM). 
 
Table 18: DMSO concentrations present in ECM during incubation of HUVECs with 
soluble dexamethasone and PPM-18. Drugs were dissolved in organic solvent prior to 
dilution in PBS and then ECM. Values are given for DMSO content for dexamethasone (10 
nM, 100 nM, and 10 µM) and PPM-18 (10 µM and 30 µM). 
Treatment DMSO concentration (%) 
Dexamethasone (10 nM) 3.29x10-7 
Dexamethasone (100 nM) 3.29x10-5 
Dexamethasone (10 µM) 3.29x10-3 
PPM-18 (10 µM) 0.27 
PPM-18 (30 µM) 0.83 
 
Cellular phenotype response was measured to determine what changes were seen in 
HUVEC exposed to DMSO over time, and if this could cause some of the inflammatory 
response seen by PPM-18 on HUVECs. After 24h, ICAM-1 showed a slight, but not 
significant, upregulation in the presence of 1% DMSO in media. At 4 days, 2% DMSO 
showed a significant upregulation (p<0.05) when compared to all other time and 




Figure 24: ICAM-1 upregulation on HUVEC after 24 h or 4 day exposure to various 
concentrations of DMSO. HUVECs were exposed to DMSO (1%, 2%, and 5%) for 24 h or 
4 days, and analysed by flow cytometry. ICAM-1 expression is reported relative to its 
expression on control cells, HUVECs in ECM. n=3. 
* significantly different from control and all other data points ( p<0.05) 
 
HUVECs also showed a response to DMSO as measured in β1-integrin expression (Figure 
25). Again, 4 day application of 2% DMSO showed the only significant upregulation from 
control (p < 0.001). It also significantly increased from 24 h to 4 days (p<0.05). The 24 h and 
4 day time points for both 1% DMSO and 2% DMSO were significantly different from 5% 
DMSO. The 5% DMSO concentrations, although not significantly different from the controls 
showed to slightly downregulate β1-integrin. There were also fewer events for DMSO 5% 
than the lower two concentrations, which suggests there was cell death occurring. The 
changes seen in ICAM-1 and β1-integrin suggest that the presence of PPM-18 dissolved in 
DMSO in cells may be cause for some of the inflammatory and necrotic response seen 





























Figure 25: β1-integrin expression on HUVEC after 24 h or 4 day exposure to various 
concentrations of DMSO. HUVECs were exposed to DMSO (1%, 2%, and 5%) for 24 h or 
4 days, and analysed by flow cytometry.  β1-integrin expression is reported relative to its 
expression on control cells, HUVECs in ECM. n=3.  
* significant difference from control (p<0.001)  
# significant difference from all lower concentrations at both time points (p<0.05)  





































5.1 Response to soluble drug and LPS 
5.1.1 Viability response 
The in vitro model using LPS was developed to induce an inflammatory response, but not a 
toxic response, in endothelial cells. Therefore, LPS concentration was chosen based on 
increase in cell activation with no reduction in cell viability. Our LPS activation results are in 
accordance with previous studies showing that LPS stimulation for 24 h does not reduce 
corneal endothelial cell viability [145,180]. LPS has been reported to activate the apoptotic 
pathways, with caspase activation peaking at 6 h following stimulation in HUVECs, but then 
decreased by 24 h [51]. This suggests that while LPS does not cause reduced viability, it 
activates a small apoptotic response in HUVEC, and under normal conditions, this response 
can be overcome within 24 hours, leading to no significant effect in cell viability.   
Dexamethasone was first chosen as a control treatment due to its reported ability to reduce 
the apoptotic responses in endothelial cells [51,181,182].  Our results indicate that soluble 
dexamethasone is non-toxic over a range of concentrations considered therapeutic (100 nM- 
12 µM) [47]. Kerachian et al indicated that a high dose of dexamethasone (1 mM) slightly 
reduced primary HUVECs’ viability to 92% after 48 h [164], which agrees with our findings 
that soluble dexamethasone at the concentrations used herein were non toxic to endothelial 
cells.  
There is currently little research on PPM-18 activation of cells. No study has investigated 
the potential changes in cellular phenotype following PPM-18 exposure in vitro. Rather, 
focus has been on finding a compound that reduces inflammation in general. The potent anti-
inflammatory properties of PPM-18, a member of the family of 1,4-naphthoquinones, occurs 
mostly through preventing neutrophil degranulation as discovered by Lien et al [183] and his 
study suggested that it was safe to use. This was confirmed in our initial tests with PPM-18 
showing low toxicity and a potential to reduce HUVEC activation, further suggesting the 
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ability of PPM-18 to be a broader anti-inflammatory compound (i.e with target cells other 
than leukocytes). However, as described in the result section, later results with PPM-18 
showed high level of necrosis. Due to PPM-18 being on backorder for 12 months, a new 
supplier was identified and it is possible that the purity and molecular structure may have 
differed between the two suppliers. PPM-18 has been reported to be of similar structure to 
1,4-naphthoquinone, and 2-methyl-1,4-naphthoquinone [184]. Toxicity tests after 24 h have 
shown a lethal concentration in half of the cells (LC50) when exposed to 6 µM of 1,4-
naphthoquinone and 15 µM of 2-methyl-1,4-naphthoquinone [184]. Thus while these 
compounds possess anti-inflammatory properties [52,160,162,170–174], they also appear to 
have the potential to be highly toxic. This may somewhat explain the increase in necrosis 
observed when HUVEC were exposed to PPM-18.  PPM-18 exposure may have activated the 
apoptotic pathways, leaving cells still viable when the MTT tests were first performed at 24 
h.  
 
5.1.2 Endothelial cell phenotype changes following LPS stimulation 
Despite the literature suggesting changes in endothelial cell phenotype with regards to 
ICAM-1 [64,67–71], β1-integrin [73,74], PECAM-1 [75,77], CD44  [78], E-selectin [64,67–
70], and VCAM-1 [57,59,62,64,68,70] expression, our results tend to suggest otherwise. 
While ICAM-1 appeared to consistently respond to stimulation, inconsistent responses were 
obtained with the other markers. These markers were also expected to show dexamethasone 
reducing the stimulatory effect of LPS, which would have allowed for dexamethasone to 
behave as a control to the effects of the novel drug PPM-18.  
ICAM-1 is a popular cell adhesion marker to measure for HUVEC and endothelial cell 
activation in response to LPS. In all endothelial cell studies, except one co-culture study [65], 
ICAM-1 was shown to be upregulated on HUVECs after LPS stimulation for up to 48 h 
[64,67–69,82]. In primary aortic endothelial cells, this upregulation was seen by 4 h and 
maintained levels across 72 h [81]. These studies agree with the significant upregulation seen 
in our HUVEC model in response to LPS, indicating that LPS led to cell activation.  
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Activation of HUVECs and human saphenous vein endothelial cells with LPS also leads to 
VCAM-1 upregulation for treatments between 3-48 h  [65,68,164,185]. This is in 
contradiction to the response seen following LPS stimulation of our in vitro model. The 
sensitivity of saphenous vein endothelial cells to LPS may be greater than HUVEC, or these 
studies may have used a more sensitive assay to detect VCAM-1 expression (such as the 
ELISA method), which allowed them to observe a response to LPS, where we did not.  
In our experiments, no upregulation of E-selectin following LPS stimulation was observed.  
The time at which E-selectin up regulation is measured on endothelial cells following LPS 
stimulation appears to influence the ability to measure its expression. E-selectin upregulation 
on HUVECs following stimulation with LPS has been measured at times up to 16 h 
following stimulant application [67,69,82,164]. Maximal expression of LPS induced E-
selectin expression has been reported to be around 6 h for primary HUVECs [64], and 4 h in 
primary aortic endothelial cells [81]. In aortic endothelial cells, E-selectin was reduced to 
basal levels by 24 h and remained at that level up to 72 h after stimulation [81]. This 
downregulation mechanism in E-selectin expression after a short time is further supported by 
a study reporting that primary HUVECs did not expressed increased E-selectin levels 
following a 48 h stimulation with LPS [65]. All together, these observations support our 
exploratory results showing an upregulation of E-selectin at earlier time points (3 and 6 h), 
and further explains the lack of upregulation at 24 h and 4 day time points for LPS 
stimulation. 
No difference in PECAM-1 expression was observed at 18 h in LPS stimulated HUVECs 
[65], possibly due to the immediate return to basal levels past 60 min as seen by Shen et al 
[75]. Shen et al showed a peak expression of PECAM-1 in response to LPS on HUVECs at 
30 min, that was reduced back to control levels of untreated cells by 60 min [75]. Again, 
HUVECs did not express PECAM-1 following activation [77]. These HUVECs were 
stimulated with the same amount of LPS as this study used, but they were able to show the 
PECAM-1 expression appeared only very briefly after stimulus. This infers that at the time 




Since TASS and endophthalmitis are rarely presented immediately following cataract 
surgery, the time chosen to identify  cell activation and upregulation of cell receptors are 24 h 
to 4 days. As E-selectin and PECAM-1 appeared to be upregulated immediately after 
stimulus and then downregulated within 24 h, these markers of activation are not relevant for 
this in vitro model. 
CD44 was chosen as an additional marker from the more commonly investigated 
endothelial cell adhesion molecules, as it has shown to play a role in macrophage adhesion to 
endothelial cells following LPS stimulation [78]. However, there is currently little known 
about CD44 expression on endothelial cells following LPS stimulation. CD44 has been 
shown to mediate neutrophil adhesion on endothelial cells in liver sinusoids, but not in 
postsinusoidal venules [73].  Microvascular endothelial cells also did not show a change in 
CD44 expression following stimulation with LPS [186]. However, the same study also 
demonstrated that differences existed in levels of ICAM-1 expression both in baseline 
expression and LPS stimulated cells within HUVECs and microvascular endothelial cells 
[186]. This further emphasizes differences between endothelial cell types. These studies 
indicate that CD44 may only be expressed and stimulated on specific endothelial cell types, 
which may explain the lack of response seen in HUVECs in our studies.  
 
5.1.3 Phenotype changes following exposure to drug 
The use of the corticosteroid dexamethasone has been reported extensively in the literature, 
showing its effect on the expression of ICAM-1 [64,65,67–71,81,82,164], E-selectin 
[64,64,67–70,81,82,164] and VCAM-1 [57,59,62,64,65,68,68,70,82,164,185].  
Dexamethasone does not affect baseline expression of these markers in HUVECs [164] or in 
endothelial cells from other sources such as human coronary artery endothelial cells [187] or  
microvascular endothelial cells [186]. However, high concentrations of dexamethasone 
(1 mM) has shown to induce significant upregulation of three adhesion molecules, ICAM-1, 
VCAM-1, and E-selectin on endothelial cells [164]; this is probably due to dexamethasone 
reaching toxic levels [188,170]. These observations support our findings, whereby 
 
 74 
dexamethasone in the micromolar range did not upregulate or downregulate any of the 
markers of activation tested.   
Similarly to our results, Lu et al found that LPS stimulation increased ICAM-1 expression 
and that neither triptolide (30 nM) nor dexamethasone alone raised the basal ICAM-1 
expression [7].  However, in their study, both triptolide (1 - 30 nM) and dexamethasone (100 
nM) reduced the effect of LPS on ICAM-1 expression by 35% and 27% respectively. These 
discrepancies with our results may be explained by the fact that corneal fibroblasts were used 
and that LPS activation in fibroblasts may be more easily inhibited by triptolide and 
dexamethasome when compared to endothelial cells. Lu et al also measured ICAM-1 
expression using a whole cell ELISA and it is possible that it is more sensitive than flow 
cytometry in identifying changes in  ICAM-1 expression [189,190]. 
 
5.1.4 Soluble drug with LPS phenotype changes 
Dexamethasone has been used previously in an effort to reduce the inflammatory response 
and upregulation of cellular adhesion molecules in endothelial cells [164,186,170]. However, 
in primary HUVECs and microvasacular endothelial cells stimulated with LPS, 
dexamethasone at 10 µM did not significantly reduce ICAM-1 expression [186,170]. 
Additionally, an increase of ICAM-1 expression levels on microvascular endothelial cells 
and HUVECs was also observed when dexamethasone was added to LPS treated cells 
[164,186]. These results agree with our findings that dexamethasone was unable to reduce 
LPS activation in endothelial cells. 
On the other hand, other studies showing a decrease in LPS stimulation with 
dexamethasone at similar levels than the ones used in this study, contradict our findings. 
Zouki et al found treatment with dexamethasone (100 nM) inhibited approximately 60% of 
the LPS expression of E-selectin and ICAM-1 caused by LPS stimulation on human coronary 
artery endothelial cells after 4 h [187]. This observation may be due to the short time of LPS 
stimulation and/or that dexamethasone only has a limited time efficacy following treatment. 
LPS was also reported to increase VCAM-1 expression on human saphenous vein endothelial 
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cells, which dexamethasone was able to significantly reduce at levels of 10 nM and above 
[185]. These cells were pretreated with dexamethasone for 48 h before LPS stimulation 
[185], which may increase dexamethasone’s effectiveness. While Meβmer et al previously 
demonstrated that low concentration of dexamethasome was able to significantly reduce 
apoptosis induced by LPS in endothelial cells [181,182], bovine glomerular endothelial cells 
were used. It is possible that glomerular, saphenous vein, and aortic endothelial cells are 
more sensitive to stimulus. However, the inhibitory effect of dexamethasone on LPS-induced 
apoptosis also appears to be time-dependent whereby the effectiveness of dexamethasone is 
lost by 18 h [182].  This suggests that there may be a time limit on the effects of 
dexamethasone on cells. 
Some of the trends observed in upregulation were not significant, most likely due to the 
high variability of the results. Often, large differences in receptor expression existed between 
the various days of experiments. The reason for greater upregulation from control on one day 
of data collection over another is unclear, but this may be due to the passage of the HUVECs 
used in each experiment. HUVECs were observed to change morphology after five or six 
passages. When this change was observed, the cells were no longer used for assays; however, 
changes within the cell may have occurred before being visible morphologically and this may 
have influenced cell response, and caused consequent variability in the data collected. 
 
5.2 Biocompatibility of polymer and copolymer materials 
In order to understand the effects of the polymer and copolymer drug delivery system, we 
evaluated both their response as a material alone, as well as loaded with drugs.  PDMS, the 
polymer used in this study is commonly used as a biomaterial [191–195]. Depending on the 
copolymerization and the surface modifications, the biocompatible properties of PDMS can 
be further controlled  Two studies suggested that unmodified PDMS materials do not allow 
cellular proliferation. PDMS alone appears to restrict the migration of human corneal 
epithelial cells and mouse fibroblasts onto the polymer surface [191,192]. In the application 
of an IOL, this is an ideal property for the material to maintain clarity and vision. However, 
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when dealing with PDMS and cell adhesion, caution should be exercised as a study also 
reported that smooth PDMS surface allowed human fibroblasts to adhere to the material and 
grow to confluence by 7 days [193]. The ability of different copolymers to modify the 
migration of cells, including HUVECs [194], highlights how chemical/surface modification 
of these materials may influence cellular behaviour.  
PNIPAAm is typically used as a copolymer in combination with surface treatments to 
modify the biological response. Except for one study showing pNIPAAm reducing 3T3 
fibroblast viability [196], pNIPAAm as part of various copolymer systems appears to be 
biocompatible.   No decrease in cell viability on ECV304 human endothelial cells [197] or 
mouse 3T3 fibroblasts [198] were observed. pNIPAAm also increased the affinity of 
hydroxyapatite to marrow stromal cells [199], and allowed in vivo rabbit corneal epithelial 
regrowth [200].   This confirms our observations that PDMS and pNIPAAm themselves are 
non toxic to a variety of cell types, including HUVECs.  
 
5.2.1 Drug delivering materials 
In this study, PPM-18 loaded materials showed a significant increase in expression of cell 
adhesion markers ICAM-1, VCAM-1, and CD44. In vitro biocompatibility studies with drug 
delivering materials often focuses on cellular viability without further analysis of cellular 
response. This presents challenges when comparing our polymer and copolymer cellular 
responses to others reviewed in the literature.  
Dexamethasone loaded polymers have been shown to be biocompatible. In the 
dexamethasone posterior segment drug delivery system by Allergan Inc, the device showed a 
significant improvement in visual acuity in the treatment of macular edema compared to a 
non-treated group [105]. Another dexamethasone implant by Siqueira et al also reduced 
inflammation seen in an in vivo rabbit model following cataract surgery [47]. However, the 
reduction in inflammation was not seen until 6 or 9 days following implantation [47], which 
may explain why after 4 days no changes were observed in our in vitro studies.  On the other 
hand, a PDMS copolymer dexamethasone drug delivery system has led to a significant 
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decrease in viability when applied to Murine L929 fibroblasts [201]. Their lowest 
dexamethasone loading corresponded to the highest we measured, which suggests that at 
higher concentrations, dexamethasone may be toxic or that some toxic interactions between 
drug and polymer may occur at these levels.  Another study also found 100 nM of soluble 
dexamethasone significantly inhibited cell growth [201].  This may explain our observations 
of 100 nM dexamethasone copolymer inducing an initial change in morphology along with a 
dramatic necrotic response.  
The polymers used as well as the drug and the drug loading protocol all play a role in the 
biocompatibility of a drug delivery device. The ability to effectively remove all of the 
solvents and unreacted monomer present in the polymer also will impact biocompatibility. 
This is clearly shown with respect to ICAM-1 in Table 16, and the variation between 
different batches of polymers. This may explain the increase necrosis seen with PPM-18 
polymer copolymer compared to the soluble PPM-18 results. Despite a stringent purification 
procedure, there is a possibility that during polymerization of our polymer and copolymer, or 
loading with PPM-18 solvent residues remain within the material. These may then leach out 
during incubation with cells, leading to upregulation of activation markers on cells. Briganti 
et al investigated this possibility with PDMS extracts through application to HUVECs to 
determine their possible toxicity from THF used in synthesis, but they saw no significant 
toxicity [195]. There is a possibility that in this study some of the toxicity seen was due to the 
interaction of PPM-18 loading and the copolymer material or polymerization process. This 
sensitivity to the materials seemed to be dependent on activation marker used. ICAM-1 
appears to be highly sensitive to chemical presence; whereas VCAM-1 appears to be less 
sensitive to chemical interaction, and primarily responded to interaction with foreign 
material.  
 
5.2.2 DMSO and drug loading response on materials 
Dexamethasone and PPM-18 were dissolved in organic solvents prior to direct incubation 
with cells or loading into the biomaterials. The possibility that this may induce a toxic 
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response to cells without LPS stimulation was investigated, and indicated a reduction in 
viability even at 1%. The lower cell activation seen at 5% was probably due to cell death, 
from the low event count observed during flow cytometry due to DMSO causing necrosis of 
cells. At levels of DMSO application less than that used for our soluble PPM-18 drug 
delivery, apoptotic markers have been expressed on HUVECs [202] and retinal pigment 
epithelial cells [203]. DMSO at 2% was also reported to cause damage after 10 min in vitro 
on human CEC [204], further indicating the sensitivity of endothelial cells to DMSO in vitro. 
The ability of DMSO to activate HUVECs at low levels suggests that this may explain the 
toxicity seen by PPM-18 when applied to cells, and possibly during drug delivery from the 
material. The concentration of DMSO applied with PPM-18 treatments could not be reduced 





Conclusions and Future Work 
6.1 Conclusions 
From this study, we have effectively created an in vitro model for analyzing the activation of 
HUVECs to LPS stimulus over 4 days for ICAM-1. PECAM-1 and E-selectin are only 
acutely expressed on HUVECs following LPS stimulus, and are downregulated within 24 h, 
which makes them unsuitable markers for further testing within this model. Dexamethasone 
(10 nM-10 µM) was ineffective in reducing LPS upregulation in HUVECs, which means 
further work is needed to identify a more effective drug to inhibit HUVEC response to LPS 
stimulus. Significant  necrosis was seen in soluble PPM-18 as well as in PPM-18 loaded 
polymer and copolymer materials, which may be due to DMSO as a solubilising agent, as 
well as PPM-18 itself. A similar response was seen in the higher level (100 nM) of drug 
delivering dexamethasone polymer and copolymer materials that lead to severe necrosis of 
cells. Neither drug nor drug delivering system proved successful in reducing LPS stimulation 
on cells. Further work is required to determine the possible mechanisms for this response, 
along with the refinement of our in vitro TASS model.  
 
6.2 Future work 
Following the analysis of the tests and results with soluble drugs and materials, there are a 
number of assays suggested to further improve and validate our model. 
Due to the differences seen between our initial toxicity testing with PPM-18 and later 
phenotype and drug delivery, evaluation of the sources of our drugs may be necessary. 
Testing different sources, and achieving consistent results would assist with replication and 
strengthen our results. While general cytokine inhibitors, such as triptolide, can be used, 




It is also possible that our materials support cell growth; cell proliferation on the surface is 
not desired as a property of a material to be used as an IOL and it is thus recommended that 
the potential for endothelial cell growth on these materials be examined. HUVEC adhesion 
on the materials would have a significant impact on the results but also on the way the drug 
delivery materials are tested (well insert versus direct contact incubation).  
Tight junctions play an integral part of the function and mechanism of the corneal 
endothelium. The presence of these junctions in HUVECs should be evaluated to further 
confirm their usefulness as a cell line for CEC. This can be done with antibody staining 
against ZO-1, claudins, and JAM-A for fluorescence microscopy. As there may be specific 
conditions, such as surface coating or time requirements for these tight junctions to form, our 
in vitro model would have to be modified accordingly to allow for their evaluation.  
It would also be beneficial to have the drug delivery in vitro model occur in a physiological 
environment closer to the anterior segment of the eye. BSSplus (Alcon Laboratories Inc, Fort 
Worth, USA) is an irrigating solution used during cataract surgery. It has a composition very 
similar to that found in the anterior segment. Evaluation of this solution may be performed to 
compare cellular responses between ECM and BSSplus.  
Co-culturing various cell types may lead to better in vitro models [27]. Future work may 
explore co-culture of macrophages with HUVECs under stimulus conditions in order to 
further investigate and model the inflammatory response observed with TASS and 
endophthalmitis.  
Finally, our model should be validated through comparison to primary CEC response. Due 
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Cytokine Cell signalling protein molecules to allow for 
intercellular communication. 
 
Cytokine Cell signalling protein molecules  and are 
often  toxic to cells. Example: TNF-α 
 
Edema An abnormal accumulation of fluid within 
the body leading to swelling. 
 
Endotoxin Toxins from Gram-negative bacteria. 
Example: LPS. 
 
Glaucoma An eye disease that relates to damage of the 
optic nerve that can lead to blindness if 
untreated. 
 
in situ Working with an entire organ or system 
outside of an organism. 
 
in vitro Biological experiments conducted with 
isolated components of an organism. 
 
in vivo Biological experiments conducted with living 
organisms in their natural state. 
 
Intracameral Pertaining to injection of drugs into the 
aqueous humour of the eye between the 
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cornea and the iris. 
 
Intraocular  Within the eye. 
 
Intravitreal In the vitreous of the eye. 
 
Keratoplasty Cornea transplantation surgery 
 
Lipopolysaccharide Large molecules consisting of a lipid and a 
polysaccharide that are present in the 
extracellular matrix of Gram negative 
material. It is an endotoxin that is not 
destroyed by sterilization. 
 
Phacoemulsion Procedure for breaking apart and removing 
the lens with ultrasound during cataract 
sugery.  
Prophylactically To protect or prevent disease. 
 
Pyrogen Fever inducing substance. 
 
Synechiae Eye condition where the iris adheres to the 
cornea or the lens. 
 
Uveitis Inflammation in the interior of the eye. 
 
Vitritis Accumulation of inflammatory cells in the 
vitreous humour or the aqueous humour. 
 
